UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 10-Q
(Mark one)
|
|
|
þ
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the quarterly period ended January 31, 2008
OR
|
|
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from
to
Commission File Number 0-17521
Zila, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
Delaware
|
|
86-0619668
|
(State or Other Jurisdiction of
|
|
(I.R.S. Employer
|
Incorporation)
|
|
Identification No.)
|
5227 North 7th Street, Phoenix, Arizona, 85014-2800
(Address of Principal Executive Offices) (Zip Code)
(602) 266-6700
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2)
has been subject to such filing requirements for the past 90 days.
Yes
þ
. No
o
.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company.
See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer
o
|
|
Accelerated filer
þ
|
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
o
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). Yes
o
. No
þ
.
As of March 1, 2008, 62,097,174 shares of the registrants common stock were outstanding.
PART I FINANCIAL INFORMATION
Item 1.
Financial Statements
ZILA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
January 31,
|
|
|
July 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Unaudited)
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
5,884,485
|
|
|
$
|
14,859,159
|
|
Trade receivables net of allowances of $172,000 and $173,000
|
|
|
5,796,537
|
|
|
|
4,273,580
|
|
Inventories net
|
|
|
4,348,208
|
|
|
|
4,074,733
|
|
Prepaid expenses and other current assets
|
|
|
1,848,577
|
|
|
|
1,646,229
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
17,877,807
|
|
|
|
24,853,701
|
|
|
Property and equipment net
|
|
|
6,033,752
|
|
|
|
6,219,436
|
|
Goodwill
|
|
|
10,171,351
|
|
|
|
10,171,351
|
|
Purchased technology net
|
|
|
9,372,245
|
|
|
|
9,884,017
|
|
Trademarks and other intangible assets net
|
|
|
10,782,935
|
|
|
|
11,555,041
|
|
Other assets
|
|
|
1,007,987
|
|
|
|
1,197,684
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
55,246,077
|
|
|
$
|
63,881,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
4,993,077
|
|
|
$
|
3,207,480
|
|
Accrued liabilities
|
|
|
4,026,520
|
|
|
|
5,587,825
|
|
Warrant and common stock repurchase liability
|
|
|
|
|
|
|
1,376,393
|
|
Current portion of deferred gain on sale leaseback
|
|
|
152,147
|
|
|
|
152,976
|
|
Short-term borrowings and current portion of long-term debt
|
|
|
261,478
|
|
|
|
77,472
|
|
Current liabilities of discontinued operations
|
|
|
173,531
|
|
|
|
165,368
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
9,606,753
|
|
|
|
10,567,514
|
|
|
|
|
|
|
|
|
|
|
Deferred gain on sale leaseback
|
|
|
|
|
|
|
75,659
|
|
Long-term debt net of current portion
|
|
|
8,119,729
|
|
|
|
7,258,569
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
17,726,482
|
|
|
|
17,901,742
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock Series B, $.001 par value - 2,500,000 shares authorized,
100,000 shares issued and outstanding, liquidation preference of $650,000
|
|
|
462,500
|
|
|
|
462,500
|
|
Common stock, $.001 par value - 147,500,000 shares authorized,
62,019,921 and 62,466,338 shares issued and outstanding
|
|
|
62,020
|
|
|
|
62,466
|
|
Additional paid-in capital
|
|
|
123,327,077
|
|
|
|
123,436,957
|
|
Accumulated deficit
|
|
|
(85,664,821
|
)
|
|
|
(76,054,251
|
)
|
Accumulated other comprehensive loss
|
|
|
(116,110
|
)
|
|
|
(127,118
|
)
|
Treasury stock, at cost (218,411 and 1,151,243 common shares)
|
|
|
(551,071
|
)
|
|
|
(1,801,066
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
37,519,595
|
|
|
|
45,979,488
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity
|
|
$
|
55,246,077
|
|
|
$
|
63,881,230
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
ZILA, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31,
|
|
|
Six Months Ended January 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
Net revenues
|
|
$
|
10,490,657
|
|
|
$
|
7,149,383
|
|
|
$
|
21,931,094
|
|
|
$
|
7,488,570
|
|
Cost of products sold
|
|
|
4,244,551
|
|
|
|
3,026,432
|
|
|
|
8,826,203
|
|
|
|
3,526,454
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
6,246,106
|
|
|
|
4,122,951
|
|
|
|
13,104,891
|
|
|
|
3,962,116
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketing and selling
|
|
|
5,220,677
|
|
|
|
3,590,311
|
|
|
|
10,517,274
|
|
|
|
5,013,358
|
|
General and administrative
|
|
|
3,128,326
|
|
|
|
3,817,195
|
|
|
|
6,602,003
|
|
|
|
6,884,635
|
|
Research and development
|
|
|
788,883
|
|
|
|
1,817,546
|
|
|
|
1,990,668
|
|
|
|
3,352,238
|
|
Depreciation and amortization
|
|
|
943,711
|
|
|
|
699,060
|
|
|
|
1,858,724
|
|
|
|
1,088,401
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(3,835,491
|
)
|
|
|
(5,801,161
|
)
|
|
|
(7,863,778
|
)
|
|
|
(12,376,516
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
73,319
|
|
|
|
180,997
|
|
|
|
197,501
|
|
|
|
276,626
|
|
Interest expense
|
|
|
(800,819
|
)
|
|
|
(790,893
|
)
|
|
|
(1,567,527
|
)
|
|
|
(5,602,023
|
)
|
Derivative income (expense)
|
|
|
|
|
|
|
|
|
|
|
(23,600
|
)
|
|
|
1,058,873
|
|
Other income (expense)
|
|
|
(25,812
|
)
|
|
|
23,561
|
|
|
|
(3,040
|
)
|
|
|
18,262
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other expense net
|
|
|
(753,312
|
)
|
|
|
(586,335
|
)
|
|
|
(1,396,666
|
)
|
|
|
(4,248,262
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
before income taxes
|
|
|
(4,588,803
|
)
|
|
|
(6,387,496
|
)
|
|
|
(9,260,444
|
)
|
|
|
(16,624,778
|
)
|
Income tax benefit (expense)
|
|
|
|
|
|
|
(54,761
|
)
|
|
|
(11,592
|
)
|
|
|
3,810,139
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
|
(4,588,803
|
)
|
|
|
(6,442,257
|
)
|
|
|
(9,272,036
|
)
|
|
|
(12,814,639
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations
|
|
|
(146,765
|
)
|
|
|
407,588
|
|
|
|
(319,034
|
)
|
|
|
(710,877
|
)
|
Gain (loss) on disposal of discontinued operations
|
|
|
|
|
|
|
(116,132
|
)
|
|
|
|
|
|
|
10,993,438
|
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,877,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income (loss) from discontinued operations
|
|
|
(146,765
|
)
|
|
|
291,456
|
|
|
|
(319,034
|
)
|
|
|
6,405,561
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(4,735,568
|
)
|
|
|
(6,150,801
|
)
|
|
|
(9,591,070
|
)
|
|
|
(6,409,078
|
)
|
Preferred stock dividends
|
|
|
9,750
|
|
|
|
9,750
|
|
|
|
19,500
|
|
|
|
19,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common shareholders
|
|
$
|
(4,745,318
|
)
|
|
$
|
(6,160,551
|
)
|
|
$
|
(9,610,570
|
)
|
|
$
|
(6,428,578
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net income (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(0.08
|
)
|
|
$
|
(0.12
|
)
|
|
$
|
(0.15
|
)
|
|
$
|
(0.25
|
)
|
Income (loss) from discontinued operations
|
|
|
|
|
|
|
0.01
|
|
|
|
(0.01
|
)
|
|
|
0.12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to common shareholders
|
|
$
|
(0.08
|
)
|
|
$
|
(0.11
|
)
|
|
$
|
(0.16
|
)
|
|
$
|
(0.13
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares
outstanding basic and diluted
|
|
|
61,478,617
|
|
|
|
55,544,636
|
|
|
|
61,441,422
|
|
|
|
50,671,338
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
ZILA, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY
For the Six Months Ended January 31, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
Total
|
|
|
|
Preferred Stock
|
|
|
Common Stock
|
|
|
Paid-in
|
|
|
Accumulated
|
|
|
Comprehensive
|
|
|
Treasury
|
|
|
Shareholders
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
Loss
|
|
|
Stock
|
|
|
Equity
|
|
Balance July 31, 2007
|
|
|
100,000
|
|
|
$
|
462,500
|
|
|
|
62,466,338
|
|
|
$
|
62,466
|
|
|
$
|
123,436,957
|
|
|
$
|
(76,054,251
|
)
|
|
$
|
(127,118
|
)
|
|
$
|
(1,801,066
|
)
|
|
$
|
45,979,488
|
|
|
Preferred stock dividends
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(19,500
|
)
|
|
|
|
|
|
|
|
|
|
|
(19,500
|
)
|
Exercise of common stock
options
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
10
|
|
|
|
11,190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,200
|
|
Stock-based compensation
expense
|
|
|
|
|
|
|
|
|
|
|
199,955
|
|
|
|
200
|
|
|
|
882,935
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
883,135
|
|
Shares issued for
payment of interest
|
|
|
|
|
|
|
|
|
|
|
276,460
|
|
|
|
277
|
|
|
|
245,057
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
245,334
|
|
Retirement of
treasury stock
|
|
|
|
|
|
|
|
|
|
|
(932,832
|
)
|
|
|
(933
|
)
|
|
|
(1,249,062
|
)
|
|
|
|
|
|
|
|
|
|
|
1,249,995
|
|
|
|
|
|
Foreign currency
translation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,008
|
|
|
|
|
|
|
|
11,008
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9,591,070
|
)
|
|
|
|
|
|
|
|
|
|
|
(9,591,070
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance January 31, 2008
|
|
|
100,000
|
|
|
$
|
462,500
|
|
|
|
62,019,921
|
|
|
$
|
62,020
|
|
|
$
|
123,327,077
|
|
|
$
|
(85,664,821
|
)
|
|
$
|
(116,110
|
)
|
|
$
|
(551,071
|
)
|
|
$
|
37,519,595
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
ZILA, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended January 31,
|
|
|
|
2008
|
|
|
2007
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(9,591,070
|
)
|
|
$
|
(6,409,078
|
)
|
Adjustments to reconcile net loss to net cash used
in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
2,084,687
|
|
|
|
1,377,583
|
|
Non-cash amortization of financing costs
|
|
|
196,190
|
|
|
|
2,255,624
|
|
Non-cash amortization of debt discounts
|
|
|
898,160
|
|
|
|
2,486,423
|
|
Non-cash interest
|
|
|
245,334
|
|
|
|
201,940
|
|
Non-cash derivative (income) expense
|
|
|
23,600
|
|
|
|
(1,058,873
|
)
|
Gain on disposal of discontinued operations
|
|
|
|
|
|
|
(10,993,438
|
)
|
Non-cash stock-based compensation expense
|
|
|
883,135
|
|
|
|
1,078,057
|
|
Other non-cash items net
|
|
|
18,026
|
|
|
|
(56,023
|
)
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Trade receivables
|
|
|
(1,522,957
|
)
|
|
|
(173,650
|
)
|
Inventories
|
|
|
(273,475
|
)
|
|
|
(247,804
|
)
|
Prepaid expenses and other assets
|
|
|
65,565
|
|
|
|
934,490
|
|
Accounts payable and accrued liabilities
|
|
|
288,106
|
|
|
|
2,786,161
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(6,684,699
|
)
|
|
|
(7,818,588
|
)
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
Additions to property and equipment
|
|
|
(549,234
|
)
|
|
|
(224,658
|
)
|
Additions to intangible assets
|
|
|
(205,510
|
)
|
|
|
(263,831
|
)
|
Proceeds from sale of assets
|
|
|
462
|
|
|
|
|
|
Restricted cash returned from collateralized letter of credit
|
|
|
|
|
|
|
3,610,950
|
|
Proceeds from disposition of discontinued operations
|
|
|
|
|
|
|
34,705,077
|
|
Acquisition of Pro-Dentec
|
|
|
|
|
|
|
(35,554,421
|
)
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities
|
|
|
(754,282
|
)
|
|
|
2,273,117
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Short-term borrowings net
|
|
|
|
|
|
|
151,296
|
|
Proceeds from convertible notes payable
|
|
|
|
|
|
|
24,075,000
|
|
Proceeds from issuance of common stock
|
|
|
11,200
|
|
|
|
15,971,481
|
|
Financing costs
|
|
|
|
|
|
|
(2,381,727
|
)
|
Principal payments on debt
|
|
|
(127,400
|
)
|
|
|
(22,841,909
|
)
|
Payment of obligation to repurchase common stock and warrants
|
|
|
(1,399,993
|
)
|
|
|
|
|
Dividends paid to preferred stockholders
|
|
|
(19,500
|
)
|
|
|
(19,500
|
)
|
|
|
|
|
|
|
|
Net cash used in financing activities
|
|
|
(1,535,693
|
)
|
|
|
14,954,641
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
(8,974,674
|
)
|
|
|
9,409,170
|
|
Cash and cash equivalents beginning of period
|
|
|
14,859,159
|
|
|
|
3,958,190
|
|
|
|
|
|
|
|
|
Cash and cash equivalents end of period
|
|
$
|
5,884,485
|
|
|
$
|
13,367,360
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Description of Business, Basis of Presentation and Continuance of Operations
The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of
Zila, Inc. and its wholly owned subsidiaries (collectively, Zila, we, us or our). Zila is
an integrated oral diagnostic company dedicated to the prevention, detection and treatment of oral
cancer and periodontal disease. During fiscal 2007, we successfully completed a multi-step
strategic redirection, which included divesting non-core businesses and acquiring the national
dental products company, Professional Dental Technologies, Inc. (Pro-Dentec).
We manufacture and market ViziLite
®
Plus with TBlue
630TM
(ViziLite
®
Plus), our flagship product for the early detection of oral abnormalities
that could lead to cancer. ViziLite
®
Plus is an adjunctive medical device cleared by the
FDA for use in a population at increased risk for oral cancer. In addition, Zila designs,
manufactures and markets a suite of proprietary products sold exclusively and directly to dental
professionals for periodontal disease, including the Rota-dent
®
Professional Powered
Brush, the Pro-Select
®
Platinum ultrasonic scaler and a portfolio of oral pharmaceutical
products for both in-office and home-care use. All of our products are marketed and sold in the
United States and Canada primarily through our direct field sales force and telemarketing
organization. Our national marketing programs reach most of the nations dental offices and
include continuing education seminars for dentists and their staffs. We are certified by the
American Dental Association and the Academy of General Dentistry to provide continuing education
seminars. Our research and development division holds expertise in pre-cancer/cancer detection
through our patented ZTC
TM
and OraTest
®
technologies and is developing a
pipeline of products focused on oral disease detection and treatment. In October 2006, we divested
our Nutraceuticals Business Unit and in May 2007 we divested our Peridex
®
brand of
prescription periodontal rinse and as a result, these operations are presented as discontinued for
all periods presented. With the integration of the operations of Pro-Dentec with our former Zila
Pharmaceuticals Business Unit and the re-alignment of our Zila Biotechnology Business Unit to serve
as our research and development division, we have organized ourselves as one operating segment in
accordance with Statement of Financial Accounting Standards (SFAS) No. 131,
Disclosures about
Segments of an Enterprise and Related Information.
These unaudited condensed consolidated financial statements have been prepared pursuant to the
rules and regulations of the Securities and Exchange Commission (the SEC). All significant
intercompany transactions and accounts have been eliminated. Certain information related to our
organization, significant accounting policies and footnote disclosures normally included in
financial statements prepared in accordance with accounting principles generally accepted in the
United States (GAAP) have been condensed or omitted. The accounting policies followed in the
preparation of these unaudited condensed consolidated financial statements are consistent with
those followed in our annual consolidated financial statements for the year ended July 31, 2007, as
filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial
statements contain all material adjustments, consisting only of normal recurring adjustments,
necessary to fairly state our financial position, results of operations and cash flows for the
periods presented and the presentations and disclosures herein are adequate when read in
conjunction with our Form 10-K for the year ended July 31, 2007. The results reported in these
interim condensed consolidated financial statements should not be regarded as being necessarily
indicative of results that might be expected for the full year. Certain reclassifications have been
made to the prior period financial statement amounts to conform to the current presentation.
The preparation of financial statements in conformity with GAAP requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenue and expenses during the reporting period. Actual results could differ from those
estimates. Significant estimates include: (i) useful lives of intangibles; (ii) impairment
analyses; (iii) depreciable lives of assets; (iv) income tax valuation allowances; (v) contingency
and litigation reserves; (vi) inventory valuation; (vii) allowances for accounts receivable, cash
discounts, sales incentives and sales returns; and (viii) valuation assumptions for share-based
payments.
The
accompanying condensed consolidated financial statements have been prepared on a going concern
basis, which assumes that Zila will be able to meet its obligations and continue its operations for
the next twelve months. We have sustained recurring losses and negative cash flows from operations
as we changed our strategic direction to focus on the growth and development of
ViziLite
®
Plus and our periodontal product lines. Our growth over the past year has been
funded through a combination of private equity, senior convertible debt and the sale of our Peridex
product line. To reduce operating losses, we have taken steps to reduce costs through restructuring
overhead and discontinuing research and development projects. We have focused our available
resources in support of our selling and marketing efforts in order to grow our revenue base. We
have plans for the improvement of gross profit through manufacturing process enhancements and
selective product price increases. With the recent authorization to sell ViziLite
®
Plus
in Canada, we have launched our international expansion initiative
and we expect to further that effort
with the launch of ViziLite
®
Plus in the United Kingdom in May 2008.
6
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of January 31, 2008, we had approximately $5.9 million of cash and cash equivalents and
$8.3 million of working capital. In order to accomplish our strategic growth objectives and to fund
our current level of operations over the next twelve months, we may be required to seek additional
funds and/or restructure our senior convertible debt. If we are unable to raise additional funds,
we may be required to delay, scale back or eliminate some of our programs for the marketing of our
products, initiate further headcount reductions and/or delay or eliminate initiatives that we
believe support future growth and profitability. There can be no
assurance that we may be
successful in executing these strategies. If we are unable to execute these strategies, we may fail
to satisfy the financial covenants of our senior secured debt and be unable to repay amounts that
could be called at the option of the debt holder. The consequences of an event of default under our
senior secured debt are discussed elsewhere herein and include, but are not limited to,
acceleration of amounts due and additional interest on amounts outstanding. These factors raise
substantial doubt about our ability to continue as a going concern. As a result, realization values
may be substantially different from carrying values as shown and these financial statements do not
give effect to adjustments that would be necessary to the carrying values and classification of
assets and liabilities should we be unable to continue as a going concern.
Basic net income (loss) per common share is computed by dividing net income (loss) available
to common shareholders by the weighted average number of common shares outstanding during the
period before giving effect to stock options, stock warrants and convertible securities
outstanding, which are considered to be dilutive common stock equivalents. Diluted net income
(loss) per common share is calculated based on the weighted average number of common and
potentially dilutive shares outstanding during the period after giving effect to convertible
preferred stock, convertible debt, stock options and warrants. Contingently issuable shares are
included in the computation of basic earnings (loss) per share when issuance of the shares is no
longer contingent. Due to the losses from continuing operations for the three and six months ended
January 31, 2008 and 2007, basic and diluted loss per common share were the same, as the effect of
potentially dilutive securities would have been anti-dilutive.
Potentially dilutive securities not included in the diluted loss per share calculation, due to
net losses from continuing operations, are as follows (unaudited) (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31,
|
|
|
Six Months Ended January 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
Options and warrants to purchase common shares
|
|
|
44
|
|
|
|
436
|
|
|
|
62
|
|
|
|
440
|
|
Common stock awards
|
|
|
51
|
|
|
|
13
|
|
|
|
52
|
|
|
|
7
|
|
Convertible preferred stock
|
|
|
100
|
|
|
|
100
|
|
|
|
100
|
|
|
|
100
|
|
Convertible secured notes
|
|
|
|
|
|
|
2,846
|
|
|
|
|
|
|
|
1,423
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total potentially dilutive securities
|
|
|
195
|
|
|
|
3,395
|
|
|
|
214
|
|
|
|
1,970
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of January 31, 2008, we have approximately $12.0 million of Amended and Restated Secured
Notes outstanding that are convertible into 5,454,546 shares of our common stock, which have been
excluded from the above table for the three and six months ended
January 31, 2008 since the conversion price of these notes is antidilutive.
2. Recently Issued Accounting Pronouncements and Adopted Accounting
In July 2006, the Financial Accounting Standards Board (FASB) issued SFAS Interpretation No.
48,
Accounting for Uncertainty in Income Taxes an interpretation of FASB Statement No. 109
(FIN 48), which we have adopted effective August 1, 2007. FIN 48 applies to all tax positions
accounted for under SFAS No. 109. FIN 48 refers to tax positions as positions taken in a
previously filed tax return or positions expected to be taken in a future tax return, which are
reflected in measuring current or deferred income tax assets and liabilities reported in the
financial statements. FIN 48 further clarifies a tax position to include, but not be limited to,
the following:
|
|
|
an allocation or a shift of income between taxing jurisdictions,
|
|
|
|
|
the characterization of income or a decision to exclude reporting taxable income in a
tax return, or
|
|
|
|
|
a decision to classify a transaction, entity or other position in a tax return as tax
exempt.
|
FIN 48 clarifies that a tax benefit may be reflected in the financial statements only if it is
more likely than not that a company will be able to sustain the tax position, based on its
technical merits. If a tax benefit meets this criterion, it should be measured and recognized based
on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. This
is a change from previous practice, whereby companies may have recognized a tax benefit only if it
was probable a tax position would be sustained.
FIN 48 also requires that we make qualitative and quantitative disclosures, including a
discussion of reasonably possible changes that might occur in unrecognized tax benefits over the
next 12 months, a description of open tax years by major jurisdictions, and a
7
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
roll-forward of all unrecognized tax benefits, presented as a reconciliation of the beginning
and ending balances of the unrecognized tax benefits on an aggregated basis.
We are potentially subject to tax audits in the United States and Canada. Tax audits by their
very nature are often complex and can require several years to complete. We are potentially
subject to United States federal and state tax examinations for the tax years ended July 31, 1994
through July 31, 2007. All tax loss years through July 31, 2007 remain open for federal, state and
foreign operations. As a condition of the acquisition of Pro-Dentec, the merger agreement related
thereto required that the selling shareholders of Pro-Dentec indemnify Zila for any identified tax
liabilities for periods prior to the acquisition. Zilas responsibility for Canadian and Canadian
Provincial income taxes arose through the acquisition of Pro-Dentec. Zila is only responsible for
Canadian and Canadian Provincial tax examinations that may arise for the tax year ended July 31,
2007 and thereafter.
The adoption of FIN 48 did not have a material impact on our financial statements or
disclosures. As of August 1, 2007 and January 31, 2008 we did not recognize any assets or
liabilities for unrecognized tax benefits relative to uncertain tax positions nor do we anticipate
any significant unrecognized tax benefits will be recorded during the next 12 months. Any interest
or penalties resulting from examinations will be recognized as a component of the income tax
provision. However, since there are no unrecognized tax benefits as a result of tax positions
taken, there are no accrued interest and penalties.
In September 2006, the FASB issued SFAS No. 157,
Fair Value Measures
(SFAS 157). SFAS 157
defines fair value, establishes a framework for measuring fair value in GAAP, expands disclosures
about fair value measurements and applies under other accounting pronouncements that require or
permit fair value measurements. SFAS 157 does not require any new fair value measurements. However,
the FASB anticipates that for some entities, the application of SFAS 157 will change current
practice. SFAS 157 is effective for financial statements issued for fiscal years beginning after
November 15, 2007, which for us will be our fiscal year beginning August 1, 2008. However, in
February 2008, the FASB deferred the effective date of SFAS 157 for one year for certain
non-financial assets and non-financial liabilities, except those that are recognized or disclosed
at fair value in the financial statements on a recurring basis (i.e., at least annually). We are
currently evaluating the impact of SFAS 157 to determine whether its adoption will have a material
effect on our consolidated financial statements.
In February 2007, the FASB issued SFAS No. 159,
The Fair Value Option for Financial Assets
and Financial Liabilities Including an Amendment of FASB Statement No. 115, Accounting for
Certain Investments in Debt and Equity Securities
(SFAS 159). SFAS 159 permits an entity to
choose to measure many financial instruments and certain items at fair value. The objective of this
standard is to improve financial reporting by providing entities with the opportunity to mitigate
volatility in reporting earnings caused by measuring related assets and liabilities differently
without having to apply complex hedge accounting provisions. SFAS 159 permits all entities to
choose to measure eligible items at fair value at specified election dates. Entities will report
unrealized gains and losses on items for which the fair value option has been elected in earnings
at each subsequent reporting date. The fair value option: (i) may be applied instrument by
instrument, with a few exceptions, such as investments accounted for by the equity method; (ii) is
irrevocable (unless a new election date occurs); and (iii) is applied only to entire instruments
and not to portions of instruments. SFAS 159 is effective as of the beginning of an entitys first
fiscal year that begins after November 15, 2007, which for us would be our fiscal year beginning
August 1, 2008. We are currently evaluating whether to adopt SFAS 159.
In December 2007, the FASB issued SFAS No. 141 (revised 2007),
Business Combinations
(SFAS
141(R)). SFAS 141(R) establishes the principles and requirements for how an acquirer: (i)
recognizes and measures in its financial statements the identifiable assets acquired, the
liabilities assumed and any noncontrolling interest in the acquiree; (ii) recognizes and measures
goodwill acquired in a business combination or a gain from a bargain purchase; and (iii)
determines what information to disclose to enable users of the financial statements to evaluate the
nature and financial effects of a business combination. SFAS 141(R) is to be applied
prospectively to business combinations consummated on or after the beginning of the first annual
reporting period on or after December 15, 2008, with early adoption prohibited. We are currently
evaluating the impact SFAS 141(R) will have upon adoption on our accounting for future
acquisitions.
In December 2007, the FASB issued SFAS No. 160,
Noncontrolling Interests in Consolidated
Financial Statements an amendment of ARB No. 51
(SFAS 160). SFAS 160 establishes accounting
and reporting standards that require (i) noncontrolling interests to be reported as a component of
equity, (ii) changes in a parents ownership interest while the parent retains its controlling
interest to be accounted for as equity transactions, and (iii) any retained noncontrolling equity
investment upon the deconsolidation of a subsidiary to be initially measured at fair value. SFAS
160 is effective for fiscal years and interim periods within those fiscal years, beginning on or
after December 15, 2008, with early adoption prohibited. We do not expect the adoption of SFAS 160
to have a material effect on our financial position or results of operations.
8
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
3. Acquisition of Pro-Dentec
On November 28, 2006, we completed the acquisition of Pro-Dentec, a privately-held,
professional dental products company headquartered in Batesville, Arkansas, for approximately $35.6
million in cash. Through its national sales and marketing organization, Pro-Dentec offers,
directly to dental professionals, a small suite of proprietary dental products that complement our
oral cancer screening products.
The following pro forma unaudited condensed statement of operations data shows the results of
our operations for the three and six months ended January 31, 2007 as if the Pro-Dentec acquisition
had occurred at the beginning of fiscal 2007 (in thousands except share amounts):
|
|
|
|
|
|
|
|
|
|
|
Three Months
|
|
|
Six Months
|
|
|
|
Ended
|
|
|
Ended
|
|
|
|
January 31, 2007
|
|
|
January 31, 2007
|
|
Net revenues
|
|
$
|
9,806
|
|
|
$
|
19,107
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(6,376
|
)
|
|
$
|
(11,881
|
)
|
|
|
|
|
|
|
|
Basic and diluted net loss per common share from continuing operations
|
|
$
|
(0.10
|
)
|
|
$
|
(0.19
|
)
|
|
|
|
|
|
|
|
Pro forma weighted average common shares outstanding basic and diluted
|
|
|
61,812
|
|
|
|
61,805
|
|
|
|
|
|
|
|
|
The above pro forma disclosure is provided for the three and six months ended January 31, 2007
because the completion of the acquisition of Pro-Dentec did not occur until November 28, 2006. No
pro forma disclosure has been presented for the three and six months ended January 31, 2008 as the
results of Pro-Dentec have been consolidated for all periods subsequent to November 2006.
4. Dispositions
As part of our strategy to focus our business operations on the development and
commercialization of products within our core business and with the highest growth potential,
during fiscal 2007 we disposed of Zila Nutraceuticals, Inc. and our Peridex
®
brand of
prescription periodontal rinse.
On August 13, 2006, we entered into a stock purchase agreement to sell Zila Nutraceuticals,
Inc., our former Nutraceuticals Business Unit, to NBTY, Inc. (NBTY). Following approval of our
shareholders, we completed the sale on October 2, 2006 for a price of $37.5 million, subject to a
working capital adjustment. The transaction resulted in the receipt of $36.4 million in cash and
expenses of $1.5 million. The sale resulted in a pre-tax gain of $11.0 million, which included the
disposition of approximately $2.9 million of goodwill previously carried by the Nutraceuticals
Business Unit. Under the stock purchase agreement, we agreed to indemnify NBTY for a number of
matters, including the breach of our representations, warranties and covenants contained in the
stock purchase agreement, in some cases until the expiration of the statute of limitations
applicable to claims related to such breaches. On September 28, 2006, as a requirement of the
Nutraceuticals disposition, we redeemed Industrial Development Revenue Bonds in the amount of $2.8
million plus accrued interest. Funds in a restricted cash collateral account were utilized for this
repayment. The balance of the restricted cash collateral was returned to Zila. We recognized a $0.2
million charge for unamortized deferred financing costs at the time of the retirement of these
bonds.
On May 31, 2007 we sold the inventory and technology related to our Peridex
®
brand
of products for $9.5 million, which had
previously been a part of our Pharmaceuticals Business Unit. Expenses of the sale were
approximately $0.1 million. This transaction resulted in a pre-tax gain of approximately $5.2
million.
During fiscal 2006 and 2005 we also divested two other business lines that had previously been
part of our Pharmaceuticals Business Unit, including the assets and certain defined liabilities of
our IST swab operations and our Zilactin
®
brand of over-the-counter lip and oral care
products. Subsequent to the sale of the Zilactin
®
products, we were engaged in an
arbitration proceeding regarding the disposition, which was settled on November 3, 2006 and
required the payment of approximately $0.7 million, which was included in loss from discontinued
operations during the first quarter of fiscal 2007. Separately, we incurred approximately $0.3
million of expense in the first six months of fiscal 2008 for pending litigation with Dr. James E.
Tinnell, which is more fully described in Note 17 Commitments and Contingencies below and relates
to the previously disposed Zilactin
®
product line.
Each of the disposals discussed above meets the definition of a component of an entity and
has been accounted for as a discontinued operation under SFAS No. 144,
Accounting for the
Impairment or Disposal of Long-Lived Assets.
The results of
9
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
operations for these businesses have
accordingly been classified as discontinued operations in all periods presented. The results of
these discontinued operations for the three and six months ended January 31, 2007 are as follows
(unaudited) (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31, 2007
|
|
|
|
Nutraceuticals
|
|
|
Pharmaceuticals
|
|
|
Total
|
|
Net revenues
|
|
$
|
|
|
|
$
|
1,387
|
|
|
$
|
1,387
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from discontinued operations
|
|
$
|
(282
|
)
|
|
$
|
689
|
|
|
$
|
407
|
|
Gain (loss) on disposal of discontinued operations
|
|
|
(114
|
)
|
|
|
(2
|
)
|
|
|
(116
|
)
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income (loss) from discontinued operations
|
|
$
|
(396
|
)
|
|
$
|
687
|
|
|
$
|
291
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended January 31, 2007
|
|
|
|
Nutraceuticals
|
|
|
Pharmaceuticals
|
|
|
Total
|
|
Net revenues
|
|
$
|
1,629
|
|
|
$
|
2,426
|
|
|
$
|
4,055
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from discontinued operations
|
|
$
|
(1,036
|
)
|
|
$
|
325
|
|
|
$
|
(711
|
)
|
Gain (loss) on disposal of discontinued operations
|
|
|
11,021
|
|
|
|
(27
|
)
|
|
|
10,994
|
|
Income tax expense
|
|
|
(3,877
|
)
|
|
|
|
|
|
|
(3,877
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income from discontinued operations
|
|
$
|
6,108
|
|
|
$
|
298
|
|
|
$
|
6,406
|
|
|
|
|
|
|
|
|
|
|
|
As of January 31, 2008 and July 31, 2007, current liabilities of the divested operations
consisted of accounts payable and other accrued expenses related to the previously divested
Pharmaceuticals operations.
5. Inventories
Inventories consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 31,
|
|
|
July 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Unaudited)
|
|
|
|
|
|
Finished goods
|
|
$
|
1,457
|
|
|
$
|
1,413
|
|
Work-in-process
|
|
|
317
|
|
|
|
323
|
|
Raw materials
|
|
|
2,811
|
|
|
|
2,659
|
|
Inventory reserves
|
|
|
(237
|
)
|
|
|
(320
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total inventories
|
|
$
|
4,348
|
|
|
$
|
4,075
|
|
|
|
|
|
|
|
|
10
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
6. Property and Equipment
Property and equipment consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 31,
|
|
|
July 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Unaudited)
|
|
|
|
|
|
Land
|
|
$
|
529
|
|
|
$
|
529
|
|
Building and improvements
|
|
|
2,077
|
|
|
|
2,181
|
|
Furniture and equipment
|
|
|
3,377
|
|
|
|
2,360
|
|
Leasehold improvements and other assets
|
|
|
828
|
|
|
|
1,360
|
|
Production, laboratory and warehouse equipment
|
|
|
4,584
|
|
|
|
4,423
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total property and equipment
|
|
|
11,395
|
|
|
|
10,853
|
|
Less: Accumulated depreciation and amortization
|
|
|
(5,361
|
)
|
|
|
(4,634
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment net
|
|
$
|
6,034
|
|
|
$
|
6,219
|
|
|
|
|
|
|
|
|
7. Goodwill and Other Intangible Assets
Goodwill and other intangible
assets consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 31, 2008 (Unaudited)
|
|
|
July 31, 2007
|
|
|
|
Gross
|
|
|
|
|
|
|
Net
|
|
|
Gross
|
|
|
|
|
|
|
Net
|
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Carrying
|
|
|
Carrying
|
|
|
Accumulated
|
|
|
Carrying
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Amount
|
|
|
Amount
|
|
|
Amortization
|
|
|
Amount
|
|
Amortizable intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased technology
|
|
$
|
15,592
|
|
|
$
|
(6,220
|
)
|
|
$
|
9,372
|
|
|
$
|
15,592
|
|
|
$
|
(5,708
|
)
|
|
$
|
9,884
|
|
Trademarks
|
|
|
151
|
|
|
|
(12
|
)
|
|
|
139
|
|
|
|
132
|
|
|
|
(11
|
)
|
|
|
121
|
|
Patents
|
|
|
2,544
|
|
|
|
(416
|
)
|
|
|
2,128
|
|
|
|
2,495
|
|
|
|
(350
|
)
|
|
|
2,145
|
|
Licensing costs
|
|
|
2,674
|
|
|
|
(1,645
|
)
|
|
|
1,029
|
|
|
|
2,674
|
|
|
|
(1,514
|
)
|
|
|
1,160
|
|
Covenants not to
compete and other
|
|
|
3,555
|
|
|
|
(1,516
|
)
|
|
|
2,039
|
|
|
|
3,556
|
|
|
|
(876
|
)
|
|
|
2,680
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total amortizable
intangible assets
|
|
|
24,516
|
|
|
|
(9,809
|
)
|
|
|
14,707
|
|
|
|
24,449
|
|
|
|
(8,459
|
)
|
|
|
15,990
|
|
Unamortizable trademarks
|
|
|
5,449
|
|
|
|
|
|
|
|
5,449
|
|
|
|
5,449
|
|
|
|
|
|
|
|
5,449
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other intangible assets
|
|
|
29,965
|
|
|
|
(9,809
|
)
|
|
|
20,156
|
|
|
|
29,898
|
|
|
|
(8,459
|
)
|
|
|
21,439
|
|
Goodwill
|
|
|
10,171
|
|
|
|
|
|
|
|
10,171
|
|
|
|
10,171
|
|
|
|
|
|
|
|
10,171
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total intangible assets
|
|
$
|
40,136
|
|
|
$
|
(9,809
|
)
|
|
$
|
30,327
|
|
|
$
|
40,069
|
|
|
$
|
(8,459
|
)
|
|
$
|
31,610
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of amortizable intangible assets is calculated using the following useful lives
(in years):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
Range of
|
|
Remaining Useful Lives
|
|
|
Useful Lives
|
|
January 31, 2008
|
|
July 31, 2007
|
|
|
|
|
|
|
(Unaudited)
|
|
|
|
|
Purchased technology
|
|
|
15
|
|
|
|
14.0
|
|
|
|
14.5
|
|
Trademarks
|
|
|
7-10
|
|
|
|
7.8
|
|
|
|
7.6
|
|
Patents
|
|
|
4-17
|
|
|
|
6.1
|
|
|
|
6.2
|
|
Licensing costs
|
|
|
7-10
|
|
|
|
3.9
|
|
|
|
4.4
|
|
Covenants not to compete and other
|
|
|
2-15
|
|
|
|
1.3
|
|
|
|
1.8
|
|
11
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
8. Accrued Liabilities
Accrued liabilities consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 31,
|
|
|
July 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Unaudited)
|
|
|
|
|
|
Accrued research and development
|
|
$
|
1,193
|
|
|
$
|
1,864
|
|
Accrued employee compensation and related taxes
|
|
|
1,278
|
|
|
|
1,876
|
|
Accrued professional and consulting fees
|
|
|
315
|
|
|
|
569
|
|
Accrued fee due Investors for Restructuring (see Note 9)
|
|
|
|
|
|
|
600
|
|
Other accrued expenses
|
|
|
1,241
|
|
|
|
679
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total accrued liabilities
|
|
$
|
4,027
|
|
|
$
|
5,588
|
|
|
|
|
|
|
|
|
9. Debt
Debt consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 31,
|
|
|
July 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Unaudited)
|
|
|
|
|
|
Short-term borrowings and current portion of long-term debt:
|
|
|
|
|
|
|
|
|
Short-term borrowings
|
|
$
|
184
|
|
|
$
|
|
|
Capital lease obligations
|
|
|
77
|
|
|
|
77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total short-term borrowings and current portion of long-term debt
|
|
$
|
261
|
|
|
$
|
77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt:
|
|
|
|
|
|
|
|
|
Senior secured convertible notes net of unamortized discount of $4,447 and $5,345
|
|
$
|
7,553
|
|
|
$
|
6,655
|
|
PharmaBio
|
|
|
500
|
|
|
|
500
|
|
Capital lease obligations
|
|
|
144
|
|
|
|
181
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total long-term debt
|
|
|
8,197
|
|
|
|
7,336
|
|
Less: Current portion of long-term debt
|
|
|
(77
|
)
|
|
|
(77
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt net of current portion
|
|
$
|
8,120
|
|
|
$
|
7,259
|
|
|
|
|
|
|
|
|
Short-term Borrowings
As of January 31, 2008, we had short-term borrowings for installments due on an insurance
policy, with an interest rate of 6.4%.
Private Placements
In November 2006, we consummated two private placements (the Private Placements) for gross
proceeds of approximately $40.0 million.
Pursuant to the first purchase agreement, we issued and sold:
|
(i)
|
|
9,100,000 shares of Zilas common stock for $1.75 per share (the Shares);
|
|
|
(ii)
|
|
Approximately $12.1 million in aggregate principal amount of 12.0% Unsecured
Convertible Notes (the Unsecured Notes), which converted into 6,900,000 shares (the
Unsecured Note Shares) of Zilas common stock at a conversion price of $1.75 per share on
December 14, 2006, the date on which our stockholders approved, among other things, the
Private Placements;
|
|
|
(iii)
|
|
Warrants to purchase approximately 5,403,000 shares of Zilas common stock, which
became exercisable in May 2007 for five years at an exercise price of $2.21 per share (the
Initial Warrants);
|
12
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
|
(iv)
|
|
Warrants to purchase approximately 3,105,000 shares of Zilas common stock, which
became exercisable for five years at an exercise price of $2.21 per share following
approval by our stockholders on December 14, 2006 (the
Additional Warrants).
|
Pursuant to the second purchase agreement, we issued and sold:
|
(i)
|
|
Approximately $12.0 million in aggregate principal amount of 6.0% Senior Secured
Convertible Notes (the Secured Notes), which are due in November 2009 and became
convertible into 5,454,546 shares of Zilas common stock at a conversion price of $2.20
following approval by our stockholders on December 14, 2006; and
|
|
|
(ii)
|
|
Warrants to purchase 1,909,091 shares of Zilas common stock, which became exercisable
for five years at an exercise price of $2.21 per share following approval by our
stockholders on December 14, 2006 (the Secured Note Warrants).
|
We granted registration rights for the Shares and shares of common stock issuable upon
conversion of the debt instruments and exercise of the warrants. A dispute arose with certain
investors (the Investors) regarding the extent of the registration rights. On August 13, 2007,
we reached an agreement with the Investors to restructure the Investors holdings (the
Restructuring) and to provide us with relief from certain financial and non-financial covenants
contained in the Secured Notes (the Amendment Agreement). As amended and restated, the Amended
and Restated Secured Notes are in the same aggregate principal amount as the Secured Notes, or
approximately $12.0 million, but are due July 31, 2010. The Amended and Restated Secured Notes
bear interest, payable quarterly, at 7.0% per annum, but at our option, interest payments can be
made at an 8.0% annual rate in shares of our common stock at a price equal to 90.0% of the average
closing bid price of such common stock for the ten trading days immediately prior to the relevant
interest payment date. The Amended and Restated Secured Notes remain convertible into shares of
common stock at a conversion price of $2.20 per share at the option of the holders of such notes.
In addition, the Amended and Restated Secured Notes contain comprehensive covenants that restrict
the way in which we can operate, and contain financial covenants that require us to:
|
(i)
|
|
Maintain, at the end of each fiscal quarter commencing with the fiscal quarter ending
July 31, 2007, free cash in an amount not less than $2.0 million; and
|
|
|
(ii)
|
|
Maintain, at the end of each of the fiscal quarters ending July 31, 2008 and
October 31, 2008, defined EBITDA of at least $1.00.
|
Failure to satisfy these financial covenants, or to maintain compliance with other covenants,
could, at the option of the Amended and Restated Secured Note holders, result in an event of
default under the Amended and Restated Secured Notes. Upon the occurrence of the first specified
event of default, the holders of the Amended and Restated Secured Notes could accelerate and demand
repayment of one-third of the outstanding principal balance and all accrued but unpaid interest on
the Amended and Restated Secured Notes. Upon the occurrence of the second specified event of
default, the holders of the Amended and Restated Secured Notes could accelerate and demand
repayment of one-half of the outstanding principal balance and all accrued but unpaid interest on
the Secured Notes. Upon the occurrence of the third specified event of default, the entire
principal balance and all accrued but unpaid interest may become due and payable. Additionally,
upon the occurrence and during the continuation of any event of default, all amounts outstanding
under the Amended and Restated Secured Notes shall bear interest at an annual rate of 15.0% per
annum.
As part of the Restructuring, we also agreed to:
|
(i)
|
|
Repurchase 932,832 Unsecured Note Shares from the Investors for approximately $1.25
million in cash, at a price based on the average closing bid price of our common stock for
the ten trading days prior to August 13, 2007, or $1.34 per Unsecured Note Share;
|
|
|
(ii)
|
|
Repurchase 227,270 Secured Note Warrants from the Investors for approximately $0.15
million in cash, at a price based on a Black-Scholes valuation, or $0.66 per Secured Note
Warrant; and
|
|
|
(iii)
|
|
Pay the Investors a $0.6 million fee.
|
The Amended and Restated Secured Notes are secured by certain of our existing and future
property, as well as the existing and future property of each of our wholly-owned subsidiaries.
Additionally, the Amendment Agreement contained a mutual release of claims. We concluded that the
Amended and Restated Secured Notes are not substantially different from the original Secured Notes
and accordingly, the Amendment Agreement has not been accounted for as a debt extinguishment. As
of July 31, 2007, the $0.6
13
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
million fee has been accrued as the resolution of the registration
rights dispute with the Investors and the fair value of the shares and warrants has been
reclassified from permanent equity to a current liability. No income or loss was recognized as a
result of this reclassification. The increase in the fair value of these financial instruments
from July 31, 2007 to the date they were repurchased on August 13, 2007 of less than $0.1 million,
has been accounted for as a charge to earnings in the first quarter of fiscal 2008.
In connection with the Restructuring and the issuance of the Amended and Restated Secured
Notes, we also received waivers from the required majority of the holders of the Initial Warrants,
Additional Warrants and Secured Note Warrants waiving any antidilution rights to which any holder
of such warrants would otherwise be entitled in connection with the issuance of any shares as
payment for interest on the Amended and Restated Secured Notes. On August 13, 2007, we entered
into a Registration Rights Agreement (the Registration Rights Agreement), which resolved certain
claims with the Investors. Separately, a side letter that imposed certain corporate governance
obligations on Zila, the most notable of which that had not yet been fulfilled was to appoint two
additional directors to our Board of Directors, was terminated.
PharmaBio Development, Inc.
In December 2002, we entered into an agreement with PharmaBio Development, Inc. (PharmaBio),
the strategic investment group of Quintiles Transnational Corp., our contract research
organization. Under this agreement, PharmaBio invested $0.5 million in us and in return we agreed
to pay PharmaBio an amount equal to 5.0% of all net sales of the OraTest
®
product in the
European Union and the United States. The aggregated amount of the royalty cannot exceed
$1.25 million and the royalty is payable quarterly. The investment was recorded as long-term debt
and will be amortized using the effective interest method.
10. Share-Based Payments
We have one active share-based stock award plan that provides for the grant of stock options
and stock awards, such as restricted stock and restricted stock units (RSUs), to our employees,
members of our Board of Directors and non-employee consultants, as approved by our Board of
Directors. We typically grant stock option awards to our employees and to members of our Board of
Directors at prices equal to the market value of our stock on the date of grant. These awards vest
over a period determined at the time of the grant and generally range from one to three years of
continuous service, with maximum terms ranging from five to ten years. Certain awards granted to
our employees provide for accelerated vesting if there is a change in control of Zila (as defined
in the plan). During December 2007, our shareholders approved an increase to the authorized shares
in our share-based stock award plan by 3,000,000 shares. As of January 31, 2008 there were
1,054,000 registered shares available for grant under the plan.
During the six months ended January 31, 2008 and 2007, we granted options to purchase
3,128,166 and 1,064,000 shares of our common stock, respectively. The fair value of options granted
is estimated using the Black-Scholes option pricing model using the following assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31,
|
|
Six Months Ended January 31,
|
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
Risk-free interest rate
|
|
|
3.5
|
%
|
|
|
5.1
|
%
|
|
|
3.5
|
%
|
|
|
5.1
|
%
|
Expected volatility
|
|
|
59.3
|
%
|
|
|
60.9
|
%
|
|
|
59.6
|
%
|
|
|
60.5
|
%
|
Expected term (in years)
|
|
|
5.2
|
|
|
|
5.9
|
|
|
|
5.2
|
|
|
|
5.1
|
|
Dividend yield
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
The risk free interest rate is based on U.S. Treasury rates with maturity dates approximating
the expected term of the grant. The historic volatility of our stock is used as the primary basis
for the expected volatility assumption. Expected term is based on evaluations of historic and
expected future employee exercise behavior. Our ability to pay dividends is restricted and
therefore we have assumed no dividend yield.
SFAS No. 123 (revised 2004),
Share-Based Payment
requires the estimation of forfeitures when
recognizing compensation expense and that this estimate of forfeitures be adjusted over the
requisite service period should actual forfeitures differ from such estimates. Changes in
estimated forfeitures are recognized through an adjustment, which is recognized in the period of
change and which impacts the amount of unamortized compensation expense to be recognized in future
periods.
14
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
A summary of stock option activity for our stock award plan for the six months ended January
31, 2008 is as follows (in thousands except exercise price per share and option term amounts)
(unaudited):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
Weighted
|
|
Average
|
|
|
|
|
|
|
|
|
Average
|
|
Remaining
|
|
Aggregate
|
|
|
Number
|
|
Exercise
|
|
Contractual
|
|
Intrinsic
|
|
|
of Options
|
|
Price
|
|
Term (Years)
|
|
Value
|
Options outstanding beginning of period
|
|
|
2,917
|
|
|
$
|
3.11
|
|
|
|
5.8
|
|
|
$
|
130
|
|
Granted
|
|
|
3,128
|
|
|
|
1.11
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(10
|
)
|
|
|
1.12
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
(220
|
)
|
|
|
2.68
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(65
|
)
|
|
|
1.84
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding end of period
|
|
|
5,750
|
|
|
|
2.06
|
|
|
|
7.6
|
|
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options vested or expected to vest end of period
|
|
|
4,863
|
|
|
|
2.15
|
|
|
|
7.3
|
|
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable end of period
|
|
|
2,268
|
|
|
|
3.00
|
|
|
|
5.3
|
|
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The weighted average grant-date fair value of options granted to our employees and directors
during the six months ended January 31, 2008 was $0.60 per common share. The total intrinsic value
of options exercised and cash received from option exercises during the six months ended January
31, 2008 was less than $0.1 million.
A summary of unvested common stock award activity within our share-based compensation plan for
the six months ended January 31, 2008 is as follows (in
thousands except grant value per share and recognition period) (unaudited):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Weighted
|
|
Average
|
|
|
|
|
|
|
Average
|
|
Remaining
|
|
|
Number
|
|
Grant
|
|
Recognition
|
|
|
of Shares
|
|
Value
|
|
Period (Years)
|
Unvested balance beginning of period
|
|
|
133
|
|
|
$
|
2.42
|
|
|
|
1.4
|
|
Granted
|
|
|
598
|
|
|
|
1.13
|
|
|
|
|
|
Vested
|
|
|
(284
|
)
|
|
|
1.52
|
|
|
|
|
|
Forfeited
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested balance end of period
|
|
|
447
|
|
|
|
1.27
|
|
|
|
1.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation costs for stock options and restricted stock grants are reflected in
the following financial statement captions (in thousands) (unaudited):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31,
|
|
|
Six Months Ended January 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
Marketing and selling expense
|
|
$
|
47
|
|
|
$
|
85
|
|
|
$
|
102
|
|
|
$
|
92
|
|
General and administrative expense
|
|
|
398
|
|
|
|
757
|
|
|
|
771
|
|
|
|
980
|
|
Research and development expense
|
|
|
1
|
|
|
|
10
|
|
|
|
2
|
|
|
|
2
|
|
Inventory
|
|
|
7
|
|
|
|
7
|
|
|
|
8
|
|
|
|
9
|
|
Discontinued operations
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
(5
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation
|
|
$
|
453
|
|
|
$
|
860
|
|
|
$
|
883
|
|
|
$
|
1,078
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The above table includes a benefit of less than $0.1 million for the first six months of
fiscal 2007 for non-employee stock options, which are adjusted to current fair value each quarter
during their vesting period as services are rendered, and is included as a component of general and
administrative expense.
15
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of January 31, 2008, total unrecognized compensation cost related to unvested stock options
and unvested common stock awards was approximately $2.5 million and $0.5 million, respectively, with a weighted average
period over which these costs are expected to be recognized of approximately 2.4 years and 1.5
years, respectively.
11. Warrants
As of January 31, 2008, we had exercisable warrants outstanding for the purchase of 12,696,500
shares of our common stock with a weighted average exercise price of $2.20 and a weighted average
contractual term of 3.8 years. We issued these warrants in connection with financing arrangements
and in connection with services provided by medical and financial advisors. These warrants were
valued using a Black-Scholes model, and the value of warrants issued for services was charged to
expense. As discussed elsewhere herein, on August 13, 2007, we repurchased 227,270 Secured Note
Warrants for approximately $0.15 million in cash.
12. Convertible Preferred Stock
On February 5, 2001, we issued 100,000 shares of Series B Convertible Preferred Stock
(Preferred Stock) as part of an acquisition. The holders of the Preferred Stock are entitled to
receive cumulative quarterly dividends at a rate of $0.0975 per share per fiscal quarter, payable
in arrears, which represents an aggregate annual dividend of $39,000. As of January 31, 2008 and
July 31, 2007, accumulated accrued dividends were $9,750. The Preferred Stock can be redeemed at
our option if our common stock maintains a closing price on each trading day equal to or greater
than $9.00 per share for any ten trading day period. The redemption price shall be the average bid
closing price of our common stock for the five trading days immediately proceeding the date we give
notice. The Preferred Stock is convertible at the option of the holder at any time on or before
December 31, 2010 into our common stock at the ratio of one-to-one. On December 31, 2010, all of
the remaining Preferred Stock will be converted into our common stock at a ratio of one-to-one.
Holders of the preferred stock have no voting rights except as required by applicable law and have
a liquidation preference of $0.65 million.
13. Treasury Stock
In connection with the Amendment Agreement described above, on August 13, 2007 we repurchased
932,832 Unsecured Note Shares from certain Investors for approximately $1.25 million in cash, at a
price based on the average closing bid price of our common stock for the ten trading days prior to
August 13, 2007, or $1.34 per Unsecured Note Share. These shares were treated as treasury stock as
of July 31, 2007, and during the first quarter of fiscal 2008 these treasury shares were retired.
During fiscal 2001, we began acquiring shares of our common stock under a stock repurchase
program announced in November 1999. The program authorized the repurchase of up to 1.0 million
shares of Zila common stock from time to time on the open market depending on market conditions and
other factors. Under this repurchase program, we purchased 225,100 shares of common stock at an
aggregate cost of approximately $0.6 million, and made the last purchases under this program in
fiscal 2003, after which we suspended purchases under the program.
14. Income Taxes
As of January 31, 2008, we have recorded a valuation allowance for our net deferred tax assets
of $15.4 million due to our lack of earnings history, and we had federal net operating loss
carryforwards of approximately $55.3 million that expire in years 2009 to 2028. Income tax expense
for the three months ended January 31, 2008 and 2007 and for the six months ended January 31, 2008
was de minimis and primarily relates to state income taxes. Income tax benefit of $3.8 million for
the six months ended January 31, 2007 resulted from the utilization of net operating loss
carryforwards to offset the income tax expense on the taxable gain on the sale of our
Nutraceuticals Business Unit, which is presented as discontinued operations.
16
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
15. Supplemental Cash Flow Information
Supplemental cash flow information is as follows (unaudited) (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended January 31,
|
|
|
2008
|
|
2007
|
Interest paid
|
|
$
|
235
|
|
|
$
|
759
|
|
Income taxes paid
|
|
|
8
|
|
|
|
139
|
|
Insurance policy financed with short-term borrowings
|
|
|
275
|
|
|
|
|
|
Conversion of Unsecured Notes
|
|
|
|
|
|
|
4,497
|
|
Capital lease obligations for new equipment
|
|
|
|
|
|
|
181
|
|
16. Comprehensive Loss
Comprehensive loss includes the effects of foreign currency translation and does not reflect
an income tax effect due to the recording of valuation allowances. Comprehensive loss is as
follows (unaudited) (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31,
|
|
|
Six Months Ended January 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
Net loss
|
|
$
|
(4,736
|
)
|
|
$
|
(6,151
|
)
|
|
$
|
(9,591
|
)
|
|
$
|
(6,409
|
)
|
Foreign currency translation adjustment
|
|
|
24
|
|
|
|
(17
|
)
|
|
|
11
|
|
|
|
(26
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss
|
|
$
|
(4,712
|
)
|
|
$
|
(6,168
|
)
|
|
$
|
(9,580
|
)
|
|
$
|
(6,435
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17. Commitments and Contingencies
Legal Proceedings
Except as described below, as of January 31, 2008, we were not a party to any pending legal
proceedings other than routine claims that arise in the ordinary conduct of our business. While we
currently believe that the ultimate outcome of these proceedings discussed below will not have a
material adverse effect on our consolidated financial condition or results of operations,
litigation is subject to inherent uncertainties. If an unfavorable ruling were to occur, there
exists the possibility of a material adverse impact on our net income in the period in which such
ruling occurs. Our estimate of the potential impact of the following legal proceedings on our
financial position and our results of operation could change in the future.
In connection with the acquisition of patent rights in 1980, we agreed to pay to Dr. James E.
Tinnell (Tinnell), the inventor of one of our former treatment compositions, a royalty of 5.0% of
gross sales of the invention disclosed in his then pending patent application. In September 2000,
we notified Tinnell that we would no longer pay such royalties because the obligations ceased in
August 1998 when the related product patents expired and we requested reimbursement of royalties
paid since August 1998. We then filed suit on November 8, 2000, in the United States District Court
for the District of Nevada requesting a declaratory judgment that we had no royalty obligations to
Tinnell and judgment for the overpaid royalties. On April 22, 2004, the Court, in part, ruled in
our favor, stating that our royalty obligations to Tinnell ceased in August 1998, however, our
request for reimbursement of overpaid royalties was dismissed. Tinnell filed a notice of appeal and
we have filed a notice of cross-appeal. On September 5, 2007, the Ninth Circuit Court of Appeals
reversed the decision of the lower court and remanded the case for a determination of whether or
not Tinnell should be credited with inventing the improvement embodied in a 1992 patent.
Indemnifications
During the normal course of business, we make certain indemnities, commitments and guarantees under
which we may be required to make payments in relation to certain transactions. These include:
(i) intellectual property indemnities to customers in connection with the use, sales and/or license
of products and services; (ii) indemnities to customers in connection with losses incurred while
performing services on their premises; (iii) indemnities to vendors and service providers
pertaining to claims based on negligence or willful misconduct; and (iv) indemnities involving the
representations and warranties in certain contracts. In addition, under our by-laws we are
committed to our directors and officers for providing for payments upon the occurrence of certain
prescribed events. The majority of these indemnities, commitments and guarantees do not provide for
any limitation on the maximum potential for future
17
ZILA, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
payments that we could be obligated to make. To help address these risks, we maintain general
business liability insurance coverage, including product, commercial, general, fiduciary,
employment practices and directors and officers liability coverages. We have not recorded a
liability for these indemnities, commitments and other guarantees.
18
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion should be read in conjunction with the Unaudited Condensed
Consolidated Financial Statements and Notes thereto included elsewhere herein as well as our Annual
Report on Form 10-K for the year ended July 31, 2007, as filed with the SEC, including the factors
set forth in the section titled Forward-looking Statements, as well as our other filings made
with the SEC.
Forward-Looking Statements
This Quarterly Report on Form 10-Q, including this Managements Discussion and Analysis of
Financial Condition and Results of Operations, contains forward-looking statements regarding future
events and our future results that are subject to the safe harbors created under the Securities Act
of 1933 (the Securities Act) and the Securities Exchange Act of 1934 (the Exchange Act). These
statements are based on current expectations, estimates, forecasts and projections about the
industries in which we operate and the beliefs and assumptions of our management. Words such as
expects, anticipates, targets, goals, projects, intends, plans, believes, seeks,
estimates, continues, may, could, foresees, should, and variations of such words and
similar expressions are intended to identify such forward-looking statements. In addition, any
statements that refer to projections of our future financial performance, our anticipated growth
and trends in our businesses, and other characterizations of future events or circumstances are
forward-looking statements. Readers are cautioned that these forward-looking statements are only
predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict,
including those identified in our Form 10-K for the year ended July 31, 2007 under Item 1A Risk
Factors, and in Item 1A, Risk Factors under Part II hereof. Therefore, actual results may differ
materially and adversely from those expressed in any forward-looking statements. We undertake no
obligation to revise or update any forward-looking statements for any reason.
Company Overview and Continuance of Operations
Zila is an integrated oral diagnostic company dedicated to the prevention, detection and
treatment of oral cancer and periodontal disease. During fiscal 2007, we successfully completed a
multi-step strategic redirection, which included divesting non-core businesses and acquiring the
national dental products company, Professional Dental Technologies, Inc. (Pro-Dentec).
We manufacture and market ViziLite
®
Plus with TBlue
630TM
(ViziLite
®
Plus), our flagship product for the early detection of oral abnormalities
that could lead to cancer. ViziLite
®
Plus is an adjunctive medical device cleared by the
FDA for use in a population at increased risk for oral cancer. During November 2007, we commenced
an international expansion initiative with the launch of ViziLite
®
Plus in Canada and we
expect to further that effort with the launch of ViziLite
®
Plus in the United Kingdom in May
2008. In addition, Zila designs, manufactures and markets a suite of proprietary products sold
exclusively and directly to dental professionals for periodontal disease, including the
Rota-dent
®
Professional Powered Brush, the Pro-Select
®
Platinum ultrasonic
scaler and a portfolio of oral pharmaceutical products for both in-office and home-care use. All
of our products are marketed and sold in the United States and Canada primarily through our direct
field sales force and telemarketing organization. Our national marketing programs reach most of
the nations dental offices and include continuing education seminars for dentists and their
staffs. We are certified by the American Dental Association and the Academy of General Dentistry to
provide continuing education seminars. Our research and development division holds expertise in
pre-cancer/cancer detection through our patented ZTC
TM
and OraTest
®
technologies and is developing a pipeline of products focused on oral disease detection and
treatment. In October 2006, we divested our Nutraceuticals Business Unit and in May 2007 we
divested our Peridex
®
brand of prescription periodontal rinse and as a result, these
operations are presented as discontinued for all periods presented. With the integration of the
operations of Pro-Dentec with our former Zila Pharmaceuticals Business Unit and the re-alignment of
our Zila Biotechnology Business Unit to serve as our research and development division, we have
organized ourselves as one operating segment.
As of January 31, 2008, we had approximately $5.9 million of cash and cash equivalents and
$8.3 million of working capital. In order to accomplish our strategic growth objectives and to fund
our current level of operations over the next twelve months, we may be required to seek additional
funds and/or restructure our senior convertible debt. If we are unable to raise additional funds,
we may be required to delay, scale back or eliminate some of our programs for the marketing of our
products, initiate further headcount reductions and/or delay or eliminate initiatives that we
believe support future growth and profitability. There can be no assurance that we will be
successful in executing these strategies. If we are unable to execute these strategies, we may fail
to satisfy the financial covenants of our senior secured debt and be unable to repay amounts that
could be called at the option of the debt holder. The consequences of an event of default under our
senior secured debt are discussed elsewhere herein and include, but are not limited to,
acceleration of amounts due and additional interest on amounts outstanding. These factors raise
substantial doubt about our ability to continue as a going concern. As a result, realization values
may be substantially different from carrying values as shown and these financial statements do not
give effect to adjustments that would be necessary to the carrying values and classification of
assets and liabilities should we be unable to continue as a going concern.
19
Recent Developments
On August 13, 2007, we entered into an Amendment Agreement with certain of the investors (the
Investors) in the two private placements completed in November 2006 for gross proceeds of
approximately $40.0 million (the Private Placements), to restructure their holdings, modify the
registration rights granted to these Investors and, with respect to the Investors in the senior
notes, provide relief from certain financial and non-financial covenants. We believe that the
restructuring strengthens our financial position by relaxing the minimum cash and EBITDA covenants
and allowing future interest to be paid in kind with common stock. The Amended and Restated
Secured Notes are in the same aggregate principal amount as the original 6.0% Senior Secured
Convertible Notes (the Secured Notes), but are now due July 31, 2010 and bear interest, payable
quarterly, at 7.0% per annum, but at our option, interest payments can be made at an 8.0% annual
rate in shares of our common stock at a price equal to 90.0% of the average closing bid price of
such common stock for the ten trading days immediately prior to the relevant interest payment date.
The required cash balance was reduced from $10.5 million to $2.0 million commencing July 31, 2007
and EBITDA, as defined, of at least $1.00 is required for each of the fiscal quarters ending
July 31, 2008 and October 31, 2008. As part of this agreement, we also (i) repurchased 932,832
common shares from the investors for $1.25 million in cash, (ii) repurchased 227,270 warrants from
the investors for $0.15 million in cash and (iii) paid the investors a $0.6 million fee.
As we more fully reported in our Annual Report on Form 10-K for the year ended July 31, 2007,
we recently conducted a comprehensive review of Zilas strategic direction, including all aspects
of the OraTest
®
program. The review included the history, present status and future
prospects of the OraTest
®
program, including the regulatory path to approval of
OraTest
®
with the FDA and its post-approval commercial potential and challenges. Our
strategic review also considered the growing market acceptance for its adjunctive oral cancer
screening product, ViziLite
®
Plus with T-Blue
630TM
, and the fact that we
currently have toluidine blue on the market today in the T-Blue
630TM
marker. We
believe that in order to maximize shareholder value, our resources must be directed to those
products and programs with the greatest probability of financial return. Our analysis concluded
that the incremental market potential of OraTest
®
, considering the availability of
ViziLite
®
Plus, does not justify the cost, time and uncertain study outcomes associated
with continuing the program in its current form. Also as previously reported, we initiated the
process of seeking a partner in an effort to realize the value of the ZTC
TM
platform.
ZTC
TM
, the active staining component in OraTest
®
, may have additional
applications, including the detection of high-risk lesions of the cervix, esophagus and skin. We
believe that the potential of these additional therapeutic applications could appeal to a partner.
Finally, in early October 2007, we ceased enrollment in the clinical trial and are taking the steps
necessary to capture, secure and analyze the clinical and program data obtained to date, which we
intend to use to support the growth of the ViziLite
®
Plus program.
In December 2007, the U.S. Department of Veterans Affairs awarded Zila a five-year contract to
market ViziLite
®
Plus to 58 Veterans Administration dental clinics and 154 Department of
Defense dental clinics.
20
Results of Operations
The following tables summarize our results of continuing operations and related statistical
information for the three and six months ended January 31, 2008 and 2007 (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended January 31,
|
|
|
|
|
|
|
|
% of
|
|
|
|
|
|
|
% of
|
|
|
%
|
|
|
|
2008
|
|
|
Revenue
|
|
|
2007
|
|
|
Revenue
|
|
|
Change
|
|
Net revenues
|
|
$
|
10,491
|
|
|
|
100.0
|
%
|
|
$
|
7,149
|
|
|
|
100.0
|
%
|
|
|
46.7
|
%
|
Cost of products sold
|
|
|
4,245
|
|
|
|
40.5
|
|
|
|
3,026
|
|
|
|
42.3
|
|
|
|
40.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
6,246
|
|
|
|
59.5
|
|
|
|
4,123
|
|
|
|
57.7
|
|
|
|
51.5
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketing and selling
|
|
|
5,221
|
|
|
|
49.8
|
|
|
|
3,590
|
|
|
|
50.2
|
|
|
|
45.4
|
|
General and administrative
|
|
|
3,127
|
|
|
|
29.9
|
|
|
|
3,817
|
|
|
|
53.4
|
|
|
|
(18.1
|
)
|
Research and development
|
|
|
789
|
|
|
|
7.5
|
|
|
|
1,818
|
|
|
|
25.4
|
|
|
|
(56.6
|
)
|
Depreciation and amortization
|
|
|
944
|
|
|
|
8.9
|
|
|
|
699
|
|
|
|
9.8
|
|
|
|
35.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(3,835
|
)
|
|
|
(36.6
|
)
|
|
|
(5,801
|
)
|
|
|
(81.1
|
)
|
|
|
(33.9
|
)
|
Other expense net
|
|
|
(754
|
)
|
|
|
(7.1
|
)
|
|
|
(586
|
)
|
|
|
(8.2
|
)
|
|
|
28.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
before income taxes
|
|
|
(4,589
|
)
|
|
|
(43.7
|
)
|
|
|
(6,387
|
)
|
|
|
(89.3
|
)
|
|
|
(28.2
|
)
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
|
(55
|
)
|
|
|
(0.8
|
)
|
|
|
(100.0
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(4,589
|
)
|
|
|
(43.7
|
)%
|
|
$
|
(6,442
|
)
|
|
|
(90.1
|
)%
|
|
|
(28.8
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Six Months Ended January 31,
|
|
|
|
|
|
|
|
% of
|
|
|
|
|
|
|
% of
|
|
|
%
|
|
|
|
2008
|
|
|
Revenue
|
|
|
2007
|
|
|
Revenue
|
|
|
Change
|
|
Net revenues
|
|
$
|
21,931
|
|
|
|
100.0
|
%
|
|
$
|
7,489
|
|
|
|
100.0
|
%
|
|
|
192.8
|
%
|
Cost of products sold
|
|
|
8,826
|
|
|
|
40.2
|
|
|
|
3,527
|
|
|
|
47.1
|
|
|
|
150.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
13,105
|
|
|
|
59.8
|
|
|
|
3,962
|
|
|
|
52.9
|
|
|
|
230.8
|
|
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketing and selling
|
|
|
10,517
|
|
|
|
48.0
|
|
|
|
5,013
|
|
|
|
66.9
|
|
|
|
109.8
|
|
General and administrative
|
|
|
6,602
|
|
|
|
30.1
|
|
|
|
6,885
|
|
|
|
92.0
|
|
|
|
(4.1
|
)
|
Research and development
|
|
|
1,991
|
|
|
|
9.1
|
|
|
|
3,352
|
|
|
|
44.8
|
|
|
|
(40.6
|
)
|
Depreciation and amortization
|
|
|
1,859
|
|
|
|
8.5
|
|
|
|
1,089
|
|
|
|
14.5
|
|
|
|
70.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(7,864
|
)
|
|
|
(35.9
|
)
|
|
|
(12,377
|
)
|
|
|
(165.3
|
)
|
|
|
(36.5
|
)
|
Other expense net
|
|
|
(1,396
|
)
|
|
|
(6.3
|
)
|
|
|
(4,248
|
)
|
|
|
(56.7
|
)
|
|
|
(67.1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
before income taxes
|
|
|
(9,260
|
)
|
|
|
(42.2
|
)
|
|
|
(16,625
|
)
|
|
|
(222.0
|
)
|
|
|
(44.3
|
)
|
Income tax benefit (expense)
|
|
|
(12
|
)
|
|
|
(0.1
|
)
|
|
|
3,810
|
|
|
|
50.9
|
|
|
|
(100.3
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from continuing operations
|
|
$
|
(9,272
|
)
|
|
|
(42.3
|
)%
|
|
$
|
(12,815
|
)
|
|
|
(171.1
|
)%
|
|
|
(27.6
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Revenues
Net revenues were $10.5 million and $7.1 million for the three months ended January 31, 2008
and 2007, respectively, an increase of $3.4 million or 46.7%. Net revenues were $21.9 million and
$7.5 million for the six months ended January 31, 2008 and 2007, respectively, an increase of $14.4
million or in excess of 100.0%. The growth in net revenues for the three and six months ended
January 31, 2008 is largely driven by our acquisition of Pro-Dentec on November 28, 2006, as well
as its effect on ViziLite
®
Plus net revenues. ViziLite
®
Plus net revenues
increased to $3.2 million and $6.2 million for the three and six months ended January 31, 2008,
21
respectively, an increase of 136.3% and 275.7% from the same periods in the previous year,
which is primarily a result of selling directly to dental offices through our national sales
organization. ViziLite
®
Plus net revenues were affected by our deliberate reductions in
sales to our then existing distribution channel in the first part of fiscal 2007 as we prepared to
modify our means of distribution upon the completion of the Pro-Dentec acquisition.
Gross Profit
Gross profit was $6.2 million and $4.1 million for the three months ended January 31, 2008 and
2007, respectively, an increase of $2.1 million or 51.5%. Gross profit was $13.1 million and $4.0
million for the six months ended January 31, 2008 and 2007, respectively, an increase of $9.1
million or in excess of 100.0%. Gross profit as a percentage of net revenues was 59.5% and 57.7%
for the three months ended January 31, 2008 and 2007, respectively and 59.8% and 52.9% for the six
months ended January 31, 2008 and 2007, respectively. The improved gross profit margin for the
second quarter and first six months of fiscal 2008 primarily relates to our sales of
ViziLite
®
Plus made direct to dental offices through our national sales organization, as
well as sales of other products including the Rota-dent
®
Professional Powered Brush and
the Pro-Select
®
Platinum ultrasonic scaler. Our prior-years gross profit reflects our
transition from a distributor-only business model and the impact of discounts and incentives
offered in support of the launch of ViziLite
®
Plus. The gross profit margin for the
first six months of the prior-year was also negatively impacted as a result of providing reserves
for ViziLite
®
inventory that was approaching its expiration date.
Marketing and Selling Expense
Marketing and selling expense was $5.2 million and $3.6 million for the three months ended
January 31, 2008 and 2007, respectively, an increase of $1.6 million or 45.4%. Marketing and
selling expense was $10.5 million and $5.0 million for the six months ended January 31, 2008 and
2007, respectively, an increase of $5.5 million or in excess of 100.0%. Our dedicated national
sales force, which sells directly to dental offices, represented the majority of the increase in
marketing and selling expense. Increased ViziLite
®
Plus related marketing and selling
expenditures also contributed to the overall increase, which reflects our continued efforts to
establish ViziLite
®
Plus as the standard of care for dental offices in the detection of
abnormalities.
General and Administrative Expense
General and administrative expense was $3.1 million and $3.8 million for the three months
ended January 31, 2008 and 2007, respectively, a decrease of $0.7 million or 18.1%. The decrease
in general and administrative expense primarily relates to corporate expense reductions of $0.3
million, which were implemented in the fourth quarter of fiscal 2007, and integration related costs
associated with the acquisition of Pro-Dentec in the second quarter of fiscal 2007 of $0.1 million,
offset by incremental general and administrative expenses relative to the acquisition of Pro-Dentec
of $0.1 million. Separately, non-cash general and administrative stock-based compensation expense
decreased by $0.4 million for the second quarter of fiscal 2008 compared to the same period in the
previous year.
General and administrative expense was $6.6 million and $6.9 million for the six months ended
January 31, 2008 and 2007, respectively, a decrease of $0.3 million or 4.1%. The decrease in
general and administrative expense primarily relates to corporate expense reductions of $1.0
million, which were implemented in the fourth quarter of fiscal 2007, offset by incremental general
and administrative expenses relative to the acquisition of Pro-Dentec of $0.9 million. Separately,
non-cash general and administrative stock-based compensation expense decreased by $0.2 million for
the first six months of fiscal 2008 compared to the same period in the previous year.
Research and Development Expense
Research and development expense was $0.8 million and $1.8 million for the three months ended
January 31, 2008 and 2007, respectively, a decrease of $1.0 million or 56.6%. Research and
development expense was $2.0 million and $3.4 million for the six months ended January 31, 2008 and
2007, respectively, a decrease of $1.4 million or 40.6%. We recently conducted an extensive review
and analysis of our strategic direction, including the OraTest
®
regulatory program, and
in the first quarter of fiscal 2008, we closed enrollment in the OraTest
®
clinical trial
and ceased expenditures for CMC and non-clinical aspects of the regulatory program. The
curtailment of the regulatory program is the primary driver of the overall decrease in research and
development expense. While activities continue to preserve the value of the ZTC
TM
asset, we believe that our level of expenditures for research and development in fiscal 2008 will
be substantially reduced from historical levels.
22
Depreciation and Amortization Expense
Depreciation and amortization expense was $0.9 million and $0.7 million for the three months
ended January 31, 2008 and 2007, respectively, an increase of $0.2 million or 35.1%. Depreciation
and amortization expense was $1.9 million and $1.1 million for the six months ended January 31,
2008 and 2007, respectively, an increase of $0.8 million or 70.7%. The increased level of
depreciation and amortization expense is primarily due to the acquisition of Pro-Dentec and its
related property, plant, equipment and amortizable intangible assets.
Other Expense Net
Other expense, net was $0.8 million and $0.6 million for the three months ended January 31,
2008 and 2007, respectively and $1.4 million and $4.2 million for the six months ended January 31,
2008 and 2007. Other expense primarily consists of interest expense, which is summarized as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31,
|
|
|
Six Months Ended January 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
Senior secured convertible notes
|
|
$
|
245
|
|
|
$
|
128
|
|
|
$
|
461
|
|
|
$
|
128
|
|
BDCF secured term loan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
520
|
|
Amortization of financing costs
|
|
|
97
|
|
|
|
161
|
|
|
|
196
|
|
|
|
2,384
|
|
Amortization of debt discounts
|
|
|
451
|
|
|
|
419
|
|
|
|
898
|
|
|
|
2,486
|
|
Capital leases
|
|
|
4
|
|
|
|
1
|
|
|
|
9
|
|
|
|
2
|
|
Other
|
|
|
4
|
|
|
|
82
|
|
|
|
4
|
|
|
|
82
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$
|
801
|
|
|
$
|
791
|
|
|
$
|
1,568
|
|
|
$
|
5,602
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense was $0.8 million for the three months ended January 31, 2008 and 2007.
Increased interest on our Amended and Restated Secured Notes, which relates in part to interest
being paid in kind with shares of our common stock for the second quarter of fiscal 2008, was
offset by lower amounts of non-cash amortization charges and other interest expense.
Interest expense was $1.6 million and $5.6 million for the six months ended January 31, 2008
and 2007, respectively. The decrease in interest expense for the first six months of fiscal 2008
primarily relates to interest incurred on a $20.0 million secured term loan with Black Diamond
Commercial Finance, LLC (BDCF), which was repaid in the first quarter of fiscal 2007. As a
result of this repayment, we expensed $3.6 million of unamortized debt issue costs and discounts
during the first quarter of fiscal 2007. Interest expense for the first six months of fiscal 2008
primarily relates to interest incurred on our Amended and Restated Secured Notes, which was paid in
cash in the first quarter of fiscal 2008 and in kind with shares of our common stock in the second
quarter of fiscal 2008, as well as amortization of the related financing costs and discounts.
During the first quarter of fiscal 2007 we recognized $1.1 million of non-cash derivative
income for changes in the fair value of a warrant to purchase 1,200,000 common shares that was
issued to BDCF in connection with the term loan discussed above. Prior to our adoption of FASB
Staff Position No. EITF 00-19-2,
Accounting for Registration Payment Arrangements
on November 1,
2006, we were required to account for this warrant as a freestanding derivative financial
instrument, with changes in the fair value of the warrant reported as non-cash charges or credits
to earnings. The derivative income recognized was due primarily to a decrease in the trading price
of our common stock during the first quarter of fiscal 2007.
Income Tax Benefit (Expense)
As of January 31, 2008, we have recorded a valuation allowance for our net deferred tax assets
of $15.4 million due to our lack of earnings history, and we had federal net operating loss
carryforwards of approximately $55.3 million that expire in years 2009 to 2028. Income tax expense
for the three months ended January 31, 2008 and 2007 and for the six months ended January 31, 2008
was de minimis and relates to state income taxes. Income tax benefit of $3.8 million for
the six months ended January 31, 2007 primarily resulted from the utilization of net operating loss
carryforwards to offset the income tax expense on the taxable gain on the sale of our
Nutraceuticals Business Unit, which is presented as discontinued operations.
Inflation and Seasonality
We do not believe that inflation has a unique or material effect on the operations or
financial condition of our businesses. Sales for the dental industry are generally affected by
holiday and vacation related seasonality, which impacts the number of available
23
selling days in each fiscal quarter. Subsequent to the Pro-Dentec acquisition in November
2006, we sell directly to dental professionals and accordingly, we would expect our sales to be
subject to these seasonal trends.
Liquidity and Capital Resources
Historically, our liquidity needs arise from working capital requirements, the funding of our
research and development program, the launch of our new products, acquisitions and debt service. We
have traditionally met these cash requirements through our cash and cash equivalents, financing
transactions, cash from operations, working capital management, the sale of non-core operations and
proceeds from the issuance of common stock under our employee stock option and stock purchase
programs.
Previously, our research and development program required the commitment of substantial
resources to conduct the time-consuming research and development, clinical studies and regulatory
activities necessary to bring any potential product to market and to establish production,
marketing and sales capabilities. As more fully described above, we recently evaluated the
strategic direction of Zila, including an assessment of the OraTest
®
regulatory program,
and we believe that in order to maximize shareholder value our resources must be directed to those
products and programs with the greatest probability of financial return. We believe that our
greatest potential lies within the synergies created with the acquisition of Pro-Dentec, which
increases our ability to develop and commercialize our already existing oral cancer screening
product, ViziLite
®
Plus. Our analysis concluded that the incremental market potential of
OraTest
®
, considering the availability of ViziLite
®
Plus, does not justify
the cost, time and uncertain study outcomes associated with continuing the program in its current
form. In order to pursue our strategy with our currently available funds, we believe that it is
necessary to reduce future research and development expenditures on the OraTest
®
regulatory program. Accordingly, during the first quarter of fiscal 2008, we curtailed activity
and spending related to this regulatory program. As a result of this curtailment, regulatory
program related expenses declined to $0.6 million and $1.5 million for the three and six months
ended January 31, 2008, respectively, compared to $1.6 million and $3.1 million for the three and
six months ended January 31, 2007, respectively. This represents a reduction of $1.0 million or
65.3% for the second quarter of fiscal 2008 compared to the same period in the previous year, and a
reduction of $1.6 million or 50.8% for the first six months of fiscal 2008 compared to the same
period in the previous year. While activities continue to preserve the value of the
ZTC
TM
asset, we believe that our level of expenditures for research and development in
fiscal 2008 will be substantially reduced from historic levels.
Separately, in the fourth quarter of fiscal 2007, we took actions to streamline our operations
and reduce overhead expenditures by approximately $3.0 million annually.
The
accompanying condensed consolidated financial statements have been prepared on a going concern
basis, which assumes that Zila will be able to meet its obligations and continue its operations for
the next twelve months. We have sustained recurring losses and negative cash flows from operations
as we changed our strategic direction to focus on the growth and development of
ViziLite
®
Plus and our periodontal product lines. Our growth over the past year has been
funded through a combination of private equity, senior convertible debt and the sale of our Peridex
product line. To reduce operating losses, we have taken steps to reduce costs through restructuring
overhead and discontinuing research and development projects. We have focused our available
resources in support of our selling and marketing efforts in order to grow our revenue base. We
have plans for the improvement of gross profit through manufacturing process enhancements and
selective product price increases. With the recent authorization to sell ViziLite
®
Plus
in Canada, we have launched our international expansion initiative
and we expect to further that effort
with the launch of ViziLite
®
Plus in the United Kingdom in May 2008.
As of January 31, 2008, we had approximately $5.9 million of cash and cash equivalents and
$8.3 million of working capital. In order to accomplish our strategic growth objectives and to fund
our current level of operations over the next twelve months, we may be required to seek additional
funds and/or restructure our senior convertible debt. If we are unable to raise additional funds,
we may be required to delay, scale back or eliminate some of our programs for the marketing of our
products, initiate further headcount reductions and/or delay or eliminate initiatives that we
believe support future growth and profitability. There can be no assurance that we will be
successful in executing these strategies. If we are unable to execute these strategies, we may fail
to satisfy the financial covenants of our senior secured debt and be unable to repay amounts that
could be called at the option of the debt holder. The consequences of an event of default under our
senior secured debt are discussed elsewhere herein and include, but are not limited to,
acceleration of amounts due and additional interest on amounts outstanding. These factors raise
substantial doubt about our ability to continue as a going concern. As a result, realization values
may be substantially different from carrying values as shown and these financial statements do not
give effect to adjustments that would be necessary to the carrying values and classification of
assets and liabilities should we be unable to continue as a going concern.
24
Selected cash flow and working capital information is summarized as follows (dollars in
thousands):
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended January 31,
|
|
|
2008
|
|
2007
|
Net cash used in operating activities
|
|
$
|
(6,685
|
)
|
|
$
|
(7,819
|
)
|
Net cash provided by (used in) investing
activities
|
|
|
(754
|
)
|
|
|
2,273
|
|
Net cash used in financing activities
|
|
|
(1,536
|
)
|
|
|
14,955
|
|
|
|
|
January 31,
|
|
July 31,
|
|
|
2008
|
|
2007
|
Cash and cash
equivalents
|
|
$
|
5,884
|
|
|
$
|
14,859
|
|
Working capital
|
|
|
8,271
|
|
|
|
14,286
|
|
Current ratio
|
|
|
1.9
|
|
|
|
2.4
|
|
As of January 31, 2008, our primary sources of liquidity included cash and cash equivalents of
$5.9 million compared to $14.9 million as of July 31, 2007. Our working capital was $8.3 million as
of January 31, 2008 compared to $14.3 million as of July 31, 2007. The decrease in working capital
primarily relates to our decreased cash balance, offset by increased trade receivables. Trade
receivables increased $1.5 million or 35.6%, primarily due to increased sales levels, the extension
of credit on our newly introduced Pro-Select
®
Platinum ultrasonic scaler and a reduction
in the rate of credit card payments by our customers. Our current ratio has declined to 1.9 as of
January 31, 2008 compared to 2.4 as of July 31, 2007, primarily as a result of the net decreases in
working capital outlined above.
Cash Flows from Operating Activities
Cash used in operating activities was $6.7 million and $7.8 million for the six months ended
January 31, 2008 and 2007, respectively. The decrease in cash used in operating activities
primarily relates to (i) cash flows from our Pro-Dentec operations, which were acquired during the
second quarter of fiscal 2007, (ii) synergies created as a result of the Pro-Dentec acquisition,
which increases our ability to develop and commercialize our already existing oral cancer screening
product, ViziLite
®
Plus, (iii) the elimination of cash flows from our recently disposed
Nutraceuticals Business Unit and Peridex
®
product line and (iv) the curtailment of
activity and spending related to the OraTest
®
regulatory program. Offsetting these cash
flow improvements were cash provided by (used in) working capital
components, which was $(1.4)
million and $3.3 million for the six months ended January 31, 2008 and 2007, respectively, or a
$4.7 million change. The working capital decrement for the six months ended January 31, 2008
primarily relates to increased accounts receivable balances, which is discussed
above. Cash provided by working capital changes in the first six months of fiscal 2007 relates to
increased levels of accounts payable.
Cash Flows from Investing Activities
Cash provided by (used in) investing activities was $(0.8) million and $2.3 million for the
six months ended January 31, 2008 and 2007, respectively. During the six months ended January 31,
2008 we spent $0.8 million for additional property and equipment and development of intangible
assets. Cash provided by investing activities during the first six months of fiscal 2007 relates
to net proceeds of $34.7 million from the sale of our Nutraceuticals Business Unit and $3.6 million
for the return of collateral upon the retirement of Industrial Development Revenue Bonds, which
related to the disposition of the Nutraceuticals Business Unit, offset by $35.6 million of cash
spent for the acquisition of Pro-Dentec, which was completed in the second quarter of fiscal 2007,
and $0.5 million of cash spent for additional property and equipment and the development of
intangible assets.
Cash Flows from Financing Activities
Cash provided by (used in) financing activities was $(1.5) million and $15.0 million for the
six months ended January 31, 2008 and 2007, respectively. During the first six months of fiscal
2008, we paid $1.4 million for the repurchase of common stock and warrants, which is described in
more detail elsewhere herein. During the first six months of fiscal 2007, we completed two private
placements for gross proceeds of approximately $40.0 million, which are described in more detail
elsewhere herein. Offsetting the
proceeds from these private placements were $22.8 million of debt repayments, which primarily
relates to the repayment of the BDCF credit facility and the Industrial Development Revenue Bonds.
During the first six months of fiscal 2007, we also incurred $2.4 million for financing costs.
25
Private Placements
In November 2006, we consummated the Private Placements for gross proceeds of approximately
$40.0 million.
Pursuant to the first purchase agreement, we issued and sold:
|
(i)
|
|
9,100,000 shares of Zilas common stock for $1.75 per share (the Shares);
|
|
|
(ii)
|
|
Approximately $12.1 million in aggregate principal amount of 12.0% Unsecured
Convertible Notes (the Unsecured Notes), which converted into 6,900,000 shares (the
Unsecured Note Shares) of Zilas common stock at a conversion price of $1.75 per share on
December 14, 2006, the date on which our stockholders approved, among other things, the
Private Placements;
|
|
|
(iii)
|
|
Warrants to purchase approximately 5,403,000 shares of Zilas common stock, which
became exercisable in May 2007 for five years at an exercise price of $2.21 per share (the
Initial Warrants);
|
|
|
(iv)
|
|
Warrants to purchase approximately 3,105,000 shares of Zilas common stock, which
became exercisable for five years at an exercise price of $2.21 per share following
approval by our stockholders on December 14, 2006 (the
Additional Warrants).
|
Pursuant to the second purchase agreement, we issued and sold:
|
(i)
|
|
Approximately $12.0 million in aggregate principal amount of 6.0% Secured Notes, which
are due in November 2009 and became convertible into approximately 5,454,546 shares of
Zilas common stock at a conversion price of $2.20 following approval by our stockholders
on December 14, 2006; and
|
|
|
(ii)
|
|
Warrants to purchase 1,909,091 shares of Zilas common stock, which became exercisable
for five years at an exercise price of $2.21 per share following approval by our
stockholders on December 14, 2006 (the Secured Note Warrants).
|
As more fully described in the notes to the accompanying unaudited condensed consolidated
financial statements, on August 13, 2007, we reached an agreement with certain Investors in the
Private Placements to restructure their holdings and provide relief from certain financial and
non-financial covenants contained in the Secured Notes. As more fully described elsewhere in this
filing, these Investors, and one other, had also previously disputed the extent of certain
registration rights granted in connection with the securities issued in the Private Placements. In
an effort to resolve the aforementioned dispute and to obtain covenant relief, Zila and certain of
the Investors with whom we had the dispute, agreed to take certain actions and restructure the
Investors holdings (the Restructuring). As part of the Restructuring, on August 13, 2007, Zila
entered into an Amendment Agreement (the Amendment Agreement) with Visium Balanced Offshore Fund,
Ltd., Visium Balanced Fund, LP, Visium Long Bias Offshore Fund, Ltd., Visium Long Bias Fund, LP and
Atlas Master Fund, Ltd., which provides for, among other things, the following:
|
(i)
|
|
Zila repurchased 932,832 Unsecured Note Shares from the Investors for approximately
$1.25 million in cash, at a price based on the average closing bid price of our common
stock for the ten trading days prior to August 13, 2007, or $1.34 per Unsecured Note Share;
|
|
|
(ii)
|
|
Zila repurchased 227,270 Secured Note Warrants from the Investors for approximately
$0.15 million in cash, at a price based on a Black-Scholes valuation, or $0.66 per Secured
Note Warrant;
|
|
|
(iii)
|
|
Zila and the Investors agreed to amend and restate the Secured Notes (the Amended and
Restated Secured Notes) on the terms set forth below and elsewhere herein; and
|
|
|
(iv)
|
|
Zila paid the Investors a $0.6 million fee.
|
We believe that the Restructuring strengthens our cash position by relaxing the minimum cash
and EBITDA based covenants and allows future interest to be paid in kind with common stock. The
Amended and Restated Secured Notes are in the same aggregate principal amount as the Secured Notes,
or $12.0 million, but are now due July 31, 2010. They bear interest, payable quarterly, at 7.0%
per annum, but at our option, interest payments can be made at an 8.0% annual rate in shares
of our common stock at a price equal to 90.0% of the average closing bid price of such common stock
for the 10 trading days immediately prior to the relevant interest payment date. The required cash
balance was reduced from $10.5 million to $2.0 million commencing July 31, 2007 and defined EBITDA
of at least $1.00 is required for each of the fiscal quarters ending July 31, 2008 and October 31,
2008.
26
Failure
to satisfy the financial covenants, or to maintain compliance with
other
covenants could, at the option of the Amended and Restated Secured Note holders, result in an event
of default under the Amended and Restated Secured Notes. Upon the occurrence of the first specified
event of default, the holders of the Amended and Restated Secured Notes could accelerate and demand
repayment of one-third of the outstanding principal balance and all accrued but unpaid interest.
Upon the occurrence of the second specified event of default, the holders of the Amended and
Restated Secured Notes could accelerate and demand repayment of one-half of the outstanding
principal balance and all accrued but unpaid interest. Upon the occurrence of the third specified
event of default, the entire principal balance and all accrued but unpaid interest may become due
and payable. Additionally, upon the occurrence and during the continuation of any event of default,
all amounts outstanding under the Amended and Restated Secured Notes shall bear interest at an
annual rate of 15.0% per annum.
In connection with the Restructuring and the issuance of the Amended and Restated Secured
Notes, Zila also received waivers from the required majority of the holders of the Initial
Warrants, Additional Warrants and Secured Note Warrants waiving any antidilution rights to which
any holder of such warrants would otherwise be entitled in connection with the issuance of any
shares as payment for interest on the Amended and Restated Secured Notes. Also, on August 13,
2007, Zila and the Investors entered into a Registration Rights Agreement (the Registration Rights
Agreement), which resolved certain claims with the Investors, as described further in the notes to
the accompanying unaudited condensed consolidated financial statements. Separately, a side letter
that imposed certain corporate governance obligations on Zila was terminated.
PharmaBio Investment
In December 2002, we entered into an agreement with PharmaBio Development, Inc. (PharmaBio),
the strategic investment group of Quintiles Transnational Corp., our contract research
organization. Under this agreement, PharmaBio invested $0.5 million in us and in return we agreed
to pay PharmaBio an amount equal to 5.0% of all net sales of the OraTest
®
product in the
European Union and the United States. The aggregated amount of the royalty cannot exceed
$1.25 million and the royalty is payable quarterly. The investment was recorded as long-term debt
and will be amortized using the effective interest method.
Convertible Preferred Stock
On February 5, 2001, we issued 100,000 shares of Series B Convertible Preferred Stock
(Preferred Stock) as part of an acquisition. The holders of the Preferred Stock are entitled to
receive cumulative quarterly dividends at a rate of $0.0975 per share per fiscal quarter, payable
in arrears, which represents an aggregate annual dividend of $39,000. As of January 31, 2008 and
July 31, 2007, accumulated accrued dividends were $9,750. The Preferred Stock can be redeemed at
our option if our common stock maintains a closing price on each trading day equal to or greater
than $9.00 per share for any ten trading day period. The redemption price shall be the average bid
closing price of our common stock for the five trading days immediately proceeding the date we give
notice. The Preferred Stock is convertible at the option of the holder at any time on or before
December 31, 2010 into our common stock at the ratio of one-to-one. On December 31, 2010, all of
the remaining Preferred Stock will be converted into our common stock at a ratio of one-to-one.
Holders of the preferred stock have no voting rights except as required by applicable law and have
a liquidation preference of $0.65 million.
EBITDA
We utilize EBITDA (earnings (loss) before interest, taxes, depreciation and amortization) to
monitor compliance with the covenants contained in our Amended and Restated Secured Notes, some of
which are based on EBITDA. The Amended and Restated Secured Notes are material agreements to us
and, therefore, the covenants are material to an investors understanding of our financial
condition and liquidity. Although we use EBITDA as a financial measure to monitor compliance with
debt covenants, it does not include certain material costs, expenses and other items necessary to
operate our business. Because EBITDA does not include these items, a stockholder, potential
investor or other user of our financial information should not consider this non-GAAP financial
measure as a substitute for net cash used in operating activities or as the sole indicator of our
financial performance since net cash used in operating activities provides a more complete measure
of our financial performance. In other words, EBITDA should only be used on a supplemental basis
combined with GAAP results when evaluating our financial performance.
27
The following is
a reconciliation of EBITDA to GAAP measures (unaudited) (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31,
|
|
|
Six Months Ended January 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
EBITDA
|
|
$
|
(2,947
|
)
|
|
$
|
(4,706
|
)
|
|
$
|
(6,125
|
)
|
|
$
|
585
|
|
Non-cash derivative (income) expense
|
|
|
|
|
|
|
|
|
|
|
24
|
|
|
|
(1,059
|
)
|
Gain from disposition of discontinued operations
|
|
|
|
|
|
|
117
|
|
|
|
|
|
|
|
(10,993
|
)
|
Non-cash stock-based compensation expense
|
|
|
453
|
|
|
|
860
|
|
|
|
883
|
|
|
|
1,078
|
|
Other non-cash items net
|
|
|
69
|
|
|
|
(1
|
)
|
|
|
19
|
|
|
|
(56
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Defined EBITDA (a)
|
|
|
(2,425
|
)
|
|
|
(3,730
|
)
|
|
|
(5,199
|
)
|
|
|
(10,445
|
)
|
Interest income
|
|
|
74
|
|
|
|
181
|
|
|
|
198
|
|
|
|
306
|
|
Interest expense
|
|
|
(801
|
)
|
|
|
(791
|
)
|
|
|
(1,568
|
)
|
|
|
(5,855
|
)
|
Income tax expense
|
|
|
|
|
|
|
(55
|
)
|
|
|
(11
|
)
|
|
|
(67
|
)
|
Amortization of financing costs
|
|
|
97
|
|
|
|
161
|
|
|
|
196
|
|
|
|
2,256
|
|
Amortization of debt discounts
|
|
|
451
|
|
|
|
419
|
|
|
|
898
|
|
|
|
2,486
|
|
Non-cash interest
|
|
|
245
|
|
|
|
64
|
|
|
|
245
|
|
|
|
202
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade receivables
|
|
|
423
|
|
|
|
(1,130
|
)
|
|
|
(1,523
|
)
|
|
|
(174
|
)
|
Inventories
|
|
|
(321
|
)
|
|
|
58
|
|
|
|
(274
|
)
|
|
|
(248
|
)
|
Prepaid expenses and other assets
|
|
|
(118
|
)
|
|
|
926
|
|
|
|
65
|
|
|
|
934
|
|
Accounts payable and accrued liabilities
|
|
|
17
|
|
|
|
182
|
|
|
|
288
|
|
|
|
2,786
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating
activities
|
|
$
|
(2,358
|
)
|
|
$
|
(3,715
|
)
|
|
$
|
(6,685
|
)
|
|
$
|
(7,819
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
Defined EBITDA is EBITDA as defined in the Amended and Restated Secured Note
Agreement, which is: Consolidated Net Income plus, without duplication and to the
extent reflected as a charge in the statement of Consolidated Net Income for such
period, the sum of (a) income tax expense, (b) interest expense, amortization or
write-off of debt discount and debt issuance costs and commissions, discounts and other
fees and charges associated with Indebtedness, (c) depreciation and amortization
expense, (d) amortization of intangibles (including, but not limited to, goodwill) and
organization costs and (e) other non-cash items reducing Consolidated Net Income and
minus, to the extent included in the statement of such Consolidated Net Income for such
period, (x) interest income and (y) all other non-cash items increasing Consolidated
Net Income, all as determined on a consolidated basis.
|
Off-Balance Sheet Financing Arrangements
We do not have any off-balance sheet financing arrangements.
Summary of Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations are based
upon our condensed consolidated financial statements, which have been prepared pursuant to the
rules and regulations of the SEC. Certain information related to our organization, significant
accounting policies and footnote disclosures normally included in financial statements prepared in
accordance with accounting principles generally accepted in the United States have been condensed
or omitted. The preparation of the financial statements in accordance with accounting principles
generally accepted in the United States requires us to make estimates and assumptions that affect
the amounts reported in the financial statements and accompanying notes. On an ongoing basis, we
evaluate our estimates related to (i) useful lives of intangibles; (ii) impairment analyses;
(iii) depreciable lives of assets; (iv) income tax valuation allowances; (v) contingency and
litigation reserves; (vi) inventory valuation; (vii) allowances for accounts receivable, cash
discounts, sales incentives and sales returns; and (viii) valuation assumptions for share-based
payments. We base our estimates on historic experience and various other factors related to each
circumstance. Actual results could differ from those estimates based upon future events, which
could include, among other risks, changes in the business environment in which we operate and
changes in the regulations governing the manner in which we manufacture and/or sell our products.
There are several accounting policies that we believe are significant to the presentation of
our financial statements and require
managements most difficult, complex or subjective judgments about matters that are inherently
uncertain. We believe our most critical accounting policies include (i) revenue recognition; (ii)
use of estimates, which is described more fully above and (iii) the carrying values of goodwill and
other long-lived assets. Our significant accounting policies and critical accounting estimates are
disclosed more fully in our Annual Report on Form 10-K for the year ended July 31, 2007. We do not
believe there have been significant changes to our critical accounting policies and estimates
subsequent to July 31, 2007.
28
The accompanying consolidated financial statements have been prepared on a going concern
basis, which assumes that Zila will be able to meet its obligations and continue its operations for
the next twelve months. As discussed elsewhere herein, there are factors that raise substantial
doubt about our ability to continue as a going concern. As a result, realization values may be
substantially different from carrying values as shown and these financial statements do not give
effect to adjustments that would be necessary to the carrying values and classification of assets
and liabilities should we be unable to continue as a going concern. Should we be unable to execute
the strategies discussed elsewhere herein, we may be required to assess the carrying values of
certain long-lived assets and an impairment charge may be required as a result of this assessment.
Recently Issued Accounting Pronouncements and Adopted Accounting
The recently issued accounting pronouncements and adopted accounting are discussed in the
notes to the unaudited condensed consolidated financial statements included elsewhere herein.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
Our exposure to market risk for a change in interest rates relates primarily to our
investments, which consists of cash and cash equivalents. The primary objective of our investment
activities is to preserve principal while maximizing yields without significantly increasing risk.
We maintain our portfolio in high credit quality cash deposits and money market funds with carrying
values that approximate market value. Because our investments consist of cash and cash equivalents,
a hypothetical 100 basis point change in interest rates is not likely to have a material effect on
our consolidated financial statements.
We also have market risk arising from changes in foreign currency exchange rates through our
subsidiaries that conduct business in Canada and Europe and have functional currencies denominated
in Canadian dollars and British pounds. We believe that such exposure does not present a
significant risk due to the limited number of transactions and/or accounts denominated in foreign
currency.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures.
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)
under the Securities Exchange Act of 1934, as amended (the Exchange Act)) that are designed:
(i) to ensure that information required to be disclosed in the reports that we file or submit under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified
in the SECs rules and forms and (ii) to ensure that such information is accumulated and
communicated to management, including our Principal Executive Officer and Principal Financial
Officer, as appropriate, to allow for timely decisions regarding required disclosure. Our
management, with the participation of our Principal Executive Officer and Principal Financial
Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the
period covered by this report, and, based on that evaluation, our Principal Executive Officer and
Principal Financial Officer have concluded that our disclosure controls and procedures (as defined
in Rules 13a-15(e) and 15d-15(e)) are effective.
Changes in Internal Control over Financial Reporting
.
There were no changes in our internal control over financial reporting (as such term is
defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter
that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.
Part II OTHER INFORMATION
Item 1. Legal Proceedings.
Information regarding our legal proceedings may be found under the Legal Proceedings section
of Note 17, Commitments and Contingencies to our Unaudited Condensed Consolidated Financial
Statements contained elsewhere herein.
Item 1A. Risk Factors.
Other than the risk factors below, there have been no material changes in risk factors
previously disclosed in our Form 10-K for the year ended July 31, 2007.
29
We may not be able to maintain compliance with our debt covenants in the future, which is the
principal reason we have identified a going concern consideration related to our financial
condition.
Our Amended and Restated Secured Notes contain comprehensive covenants that restrict the way
in which we can operate, and contain financial covenants that require us to:
|
(i)
|
|
Maintain, at the end of each fiscal quarter, free cash in an amount not less than $2.0
million; and
|
|
|
(ii)
|
|
Maintain, at the end of each of the fiscal quarters ending July 31, 2008 and
October 31, 2008, defined EBITDA of at least $1.00.
|
Failure to satisfy these financial covenants, or to maintain compliance with the other
covenants could, at the option of the Amended and Restated Secured Note holders, result in an event
of default under the Amended and Restated Secured Notes. Upon the occurrence of the first specified
event of default, the holders of the Amended and Restated Secured Notes could accelerate and demand
repayment of one-third of the outstanding principal balance and all accrued but unpaid interest on
the Amended and Restated Secured Notes. Upon the occurrence of the second specified event of
default, the holders of the Amended and Restated Secured Notes could accelerate and demand
repayment of one-half of the outstanding principal balance and all accrued but unpaid interest on
the Secured Notes. Upon the occurrence of the third specified event of default, the entire
principal balance and all accrued but unpaid interest may become due and payable.
As of January 31, 2008, we had approximately $5.9 million in cash and cash equivalents. We
had cash and cash equivalents of $14.9 million and $8.7 million as of July 31, 2007 and October 31,
2007, respectively. In addition, EBITDA, as defined in the Amended and Restated Secured Notes, was
$(2.4) million and $(2.8) million for the quarters ended January 31, 2008 and October 31, 2007,
respectively. Based on our current available funds and the upcoming EBITDA requirement for the
quarter ended July 31, 2008, we may be required to pursue one or more of the following strategies
in an effort to maintain compliance with the above covenants: (i) limit the marketing of our
products; (ii) raise additional funds; (iii) obtain a waiver or amendment of the foregoing
covenants; (iv) initiate further headcount reductions; and/or (v) delay or eliminate initiatives
that we believe support future growth and profitability. There can be no assurance that we will be
successful in executing these strategies. If we are unable to execute these strategies, we may
breach the financial covenants and be unable to repay the outstanding balance. In addition, our
ability to comply with these covenants and restrictions may be affected by events beyond our
control. Ultimately, based on our reduced cash balances, our recurring negative operating cash
flows and the possibility of debt covenant breaches, which could result in the acceleration of such
debt, there is substantial doubt about our ability to continue as a going concern for the next 12
months.
Our stock price may result in our failure to maintain NASDAQ Marketplace Rules related to
minimum stock price requirements which could result in NASDAQ delisting our common stock.
NASDAQ Marketplace Rules require us to maintain a closing bid price of $1.00 per share for our
common stock. In the event that our common stock closing bid price falls below $1.00 per share for
30 consecutive business days we would likely receive notice from NASDAQ that we are not in
compliance with Marketplace Rules, which could ultimately lead to the delisting of our common stock
from the NASDAQ Global Market if we were unable to maintain the requisite minimum stock price
during the subsequent probationary period. In the event that we were delisted from the NASDAQ
Global Market, our common stock would become significantly less liquid, which would adversely
affect its value. Although our common stock would likely be traded over-the-counter or on pink
sheets, these types of listings involve more risk and trade less frequently and in smaller volumes
than securities traded on the NASDAQ Global Market.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
On January 31, 2008, the Company issued an aggregate of 276,460 shares of its common stock to
the holders of its Amended and Restated Secured Notes. We issued such shares to satisfy our
obligation under the Amended and Restated Secured Notes to pay the holders an aggregate of $245,334
in interest for the three month period that ended on January 31, 2008. The issuance was exempt
from registration pursuant to Section 4(2) of the Securities Act.
Item 3. Defaults Upon Senior Securities.
None
30
Item 4. Submission of Matters to a Vote of Security Holders
.
The Company held its Annual Meeting of Stockholders in Phoenix, Arizona on December 13, 2007.
A total of 46,351,044 shares of common stock, or 75% of the outstanding shares, were represented in
person or by proxy. The results of the matters voted on at the Annual Meeting are as follows:
(i) Election of Directors:
|
|
|
|
|
|
|
|
|
|
|
Number of Shares
|
Name
|
|
For
|
|
Withheld
|
David R. Bethune
|
|
|
44,620,527
|
|
|
|
1,730,517
|
|
J. Steven Garrett
|
|
|
42,583,185
|
|
|
|
3,767,859
|
|
David Goldman
|
|
|
44,644,925
|
|
|
|
1,706,119
|
|
Leslie H. Green
|
|
|
44,199,276
|
|
|
|
2,151,768
|
|
O.B. Parrish
|
|
|
36,793,745
|
|
|
|
9,557,299
|
|
George J. Vuturo
|
|
|
44,616,590
|
|
|
|
1,734,454
|
|
Following the resignation of David Goldman on December 17, 2007, the Board of Directors is
comprised of five directors who are elected to serve until the next annual meeting of shareholders
and until their successors are elected or qualified.
(ii) Proposal to amend the 1997 Stock Award Plan to increase the total number of shares of
common stock authorized for issuance from 5.0 million shares to 8.0 million shares.
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Non Votes
|
|
|
|
|
|
|
|
23,491,942
|
|
3,436,882
|
|
388,788
|
|
19,033,432
|
(iii) The ratification of the appointment of BDO Seidman, LLP as Zila, Inc.s Independent
Registered Public Accounting Firm for the fiscal year ending July 31, 2008.
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
|
|
|
|
45,394,591
|
|
402,809
|
|
553,644
|
Item 5. Other Information.
None
Item 6. Exhibits.
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
31.1
|
|
Section 302 Certification of the Principal Executive Officer
|
|
|
|
31.2
|
|
Section 302 Certification of the Principal Financial Officer
|
|
|
|
32.1*
|
|
Section 1350 Certification of the Principal Executive Officer and Principal Financial Officer
|
31
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Date: March 11, 2008
|
|
Zila, Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ FRANK J. BELLIZZI
|
|
|
|
Frank J. Bellizzi
|
|
|
|
|
Executive Vice President
(Principal Executive Officer)
|
|
|
|
|
|
|
By:
|
/s/ DIANE E. KLEIN
|
|
|
|
Diane E. Klein
|
|
|
|
|
Vice President Finance and Treasurer
(Principal Financial Officer)
|
|
|
|
|
|
Exhibit
|
|
|
Number
|
|
Description
|
|
|
|
31.1
|
|
Section 302 Certification of the Principal Executive Officer
|
|
|
|
31.2
|
|
Section 302 Certification of the Principal Financial Officer
|
|
|
|
32.1*
|
|
Section 1350 Certification of the Principal Executive Officer and Principal Financial Officer
|
32
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024